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ABSTRACT 
 
Thoracic malignancies are one of the deadliest of all cancers, being the leading 
cause of cancer death in the Western world. Thoracic malignancies arise from different 
tissues; however the most common are of epithelial (commonly referred to as non-small 
cell lung cancer, or NSCLC), neuroendocrine (small cell lung cancer, or SCLC) and 
mesothelial origin (malignant mesothelioma, or MM). The DNA oncogenic virus Simian 
Virus 40 (SV40) has been shown to cooperate with environmental oncogenic fibers in the 
onset of MM (Bocchetta et al., 2000, Kroczynska et al., 2006). Insulin like growth factor-
1 (IGF-1) signaling plays a central role in all thoracic malignancies and in the process of 
SV40-mediated malignant transformation of human cells. We have found that in SV40-
transformed human mesothelial cells (HM) the Large T antigen (Tag), p53, pRb and p300 
function in a multi-protein complex to promote transcription of the IGF1 gene. Depletion 
of p53 in these cells causes growth arrest because of lack of IGF-1 synthesis. These 
results provide a novel mechanistic and biological interpretation of the p53/Tag 
complexes and of DNA tumor virus transformation in general. It was generally believed 
that one of the major functions of Tag was to bind and inactivate the tumor suppressor 
p53. Our data, instead, support a model in which the Tag/p53 complexes are not inert, but 
rather play an active, essential role in the process of SV40-mediated transformation of 
HM, hence in the pathogenesis of MM. 
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Aside from the well-established role played by the IGF-1/Akt-1 axis in thoracic 
malignancies, we focused our research on the role of Notch signaling in cancers of the 
thorax. Notch-1 signaling has been shown to be required for the growth of SV40-
transformed human mesothelial cells (Bocchetta et al., 2003). We therefore expanded the 
studies of the role of Notch signaling in MM and NSCLC. We have found that, under 
hypoxia, the condition that best recapitulates solid tumors microenvironment, both MM 
and NSCLC cells have an elevated Notch signaling pathway as compared to normal 
human mesothelial (HM) and lung bronchioalveolar cells. Genetic and chemical 
modulation of the Notch pathway indicated that these tumor cells are dependent on Notch 
signaling. More specifically, MM and NSCLC cell survival was Notch-1 dependent. 
Notch-1 through its negative regulation of phosphatase and tensin homolog (PTEN) and 
positive regulation of the IGF-1 receptor (IGF-1R) expression causes activation of the 
pro-survival IGF-1/Akt-1 signaling pathway. These results provide new insight into the 
role of Notch in MM and lung cancer, and strongly implicate that Notch pathway 
inhibitors may be useful in the treatment of those deadly diseases. Our data indicate that 
targeting Notch-1 signaling using !-secretase inhibitors (GSI) may represent a novel, 
promising therapeutic approach for thoracic malignancies treatment, by specifically 
targeting hypoxic tumor microenvironment. This is especially important because hypoxic 
tumor microenvironment is responsible for poor response to standard anticancer 
treatment, tumor recurrence and ultimately death. These results also identify additional 
molecular targets that may snergize with Notch-1 inhibition.  
!! !  
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CHAPTER 1 
INTRODUCTION 
 
Since its discovery in 1960 as a contaminant of polio vaccines, SV40 has been the 
object of extensive studies to assess whether this DNA virus plays a role in human 
carcinogenesis. Although this issue has met a broad skepticism in the past two decades, 
an increasing amount of data has accumulated linking SV40 to specific types of human 
cancer, especially malignant mesothelioma (MM).  
Primary human mesothelial cells (HM), as compared to other cells (e.g. 
fibroblasts), are uniquely susceptible to SV40 infection/transformation. HM are able to 
survive SV40 infection since viral replication takes place at the low rate, which renders 
them subjected to the transforming activities of the SV40 oncogenes for a prolonged 
time. This translates into a uniquely high rate of SV40 mediated transformation in these 
cells (Bocchetta et al., 2000). HM transformation by SV40 is enhanced by environmental 
agents, with asbestos being a known etiological agent for MM (Cicala et al., 1993; 
Kroczynska et al., 2006).  
SV40 major oncogene, large T antigen (Tag), besides its role in an initiation of 
viral replication (Wobbe et al., 1985) and regulation of SV40 transcription (Tjian, 1981), 
also interacts with host cellular proteins. Among those, interaction with heat shock 
protein 70 (HSP70; Sullivan et al., 2000), pRb protein family members (DeCaprio et al., 
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1988) and cellular p53 (Pinhasi-Kimhi et al., 1986) appears to be the most intimately 
linked to SV40 promotion of cell cycle progression and cell transformation. Tag trans-
activates a number of genes, which protein products promote cell cycle progression, of 
which regulation of insulin like growth factor 1 (IGF-1) signaling appears to be required 
for SV40 mediated transformation of human mesothelial cells (HM; Porcu et al., 1992). 
SV40 is not able to transform mouse embryonic fibroblasts (MEF) in the absence of 
insulin like growth factor-1 receptor (IGF-1R; Sell et al., 1993). The IGF-1R docking 
protein insulin receptor substrate-1 (IRS-1; White, 1998) was found in complex with Tag, 
which resulted in protection from apoptosis (Zhou-Li et al., 1997). In Aim 1 (results 
presented in Chapter 3) we hypothesize that there is a direct transcriptional 
regulation of the IGF1 by Tag. Specifically, we tested the involvement of Tag in 
regulation of the transcription of the IGF1 in SV40 transformed HM. We sought to 
determine whether Tag mediated transactivation of IGF1 requires p53, and if so whether 
Tag/p53 complexes can associate with the IGF1 promoter. We also wanted to 
characterize the composition of the transactivator complex and determine its location in 
the promoter region.   
During the process of HM cell transformation, SV40 transcriptionaly up-regulates 
Notch-1 signaling (Bocchetta et al., 2003). Interfering with Notch-1 signaling causes 
growth arrest of SV40-transformed HM (Bocchetta et al., 2003). Increasing number of 
reports suggest pro-oncogenic role of Notch in many solid tumors, however the role of 
Notch signaling in MM is not characterized. The family of Notch receptors includes four 
isoforms, all of which can play a different role in the malignant setting. It is imperative to 
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understand what is the role of all Notch isoforms in pathogenesis of MM. Our objective 
in Aim 2 (presented in Chapter 4) is to determine what is the outcome of Notch 
signaling in MM in general (e.g., irrespective of SV40). Notch signaling can play a 
pleiotropic role, and affect signaling of other important pro-survival pathways during 
malignant transformation. We hypothesized that given the importance of IGF-1R 
signaling in malignant transformation of HM by SV40, Notch can affect the IGF-1/Akt-1 
signaling pathway promoting the pro-survival events. Since Notch signaling is dose, time 
and context dependent, in our studies we take into consideration all of these variables.  
Notch signaling has been studied more in thoracic malignancies of different 
histological derivation as compared to MM. In lung cancer there are reports suggesting 
that Notch signaling plays a role in non-small cell lung cancer (NSCLC). Our previous 
work provided evidence of the oncogenic role of Notch-1 in adenocarcinoma of the lung 
(ACL; Chen et al., 2007), the most frequently occurring type of lung cancer.  Targeting 
Notch using !-secretase inhibitor (GSI) caused ACL cell death under hypoxia, the 
condition of low oxygen concentration, which characterizes majority of solid tumor mass. 
In Aim 3 (presented in Chapter 5) we try to understand which molecular pathways 
are affected by Notch-1 signaling in ACL. Given our previous findings that the primary 
isoform that mediates ACL pro-survival effects is Notch-1 (Chen et al., 2007), we 
focused on mechanisms that mediate Notch-1 signaling. In T-cell acute lymphoblastic 
leukemia (T-ALL) Notch-1 affects Akt-1 signaling by repressing phosphatase and tensin 
homolog expression (PTEN; Palomero et al., 2007). Based on our gene expression 
studies, we hypothesized that Notch-1 can affect Akt-1 signaling pathway in ACL. In our 
!    
!  
4!
studies we wanted to validate whether expression of PTEN, the major inhibitor of Akt-1 
signaling, was affected by Notch-1. Given the evidence that hypoxia can enhance Notch-
1 transcriptional regulation (Gustafsson et al., 2005, Chen et al., 2007), and that hypoxia 
was shown to regulate IGF1 expression (Joung et al., 2007), we also looked if Notch-1 
can affect other components of the IGF-1/Akt-1 pathway.  
Understanding the molecular pathways that underlie malignant transformation of 
the two thoracic malignancies of different cell origin (epithelial versus mesothelial) 
would provide a better understanding of these malignancies, the role played by Notch 
signaling in tumors of different histological derivation, and possibly suggest novel 
treatment strategies. If indeed Notch and IGF-1/Akt-1 pathways are interconnected, 
targeting Notch signaling pathway using GSI or monoclonal antibodies may represent a 
novel and attractive treatment approach for MM and lung cancer patients. Also, 
elucidating the mechanisms that are affected by Notch signaling may reveal new 
therapeutic targets for the treatment of those deadly malignancies. 
In conclusion, our studies have unveiled a molecular circuitry, which involves 
SV40/Notch/PTEN/IGF-1 signaling that leads to MM cell survival and malignant growth. 
Surprisingly, a similar molecular network takes place in NSCLC leading to similar 
physiological outcomes. We can summarize those relationships in the following figure: 
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Figure 1. Dissertation outline 
 
 
 !"
CHAPTER 2 
        REVIEW OF THE RELATED LITERATURE 
 
2.1. THORACIC MALIGNANCIES 
 Thoracic malignancies are among the most prevalent and the most rapidly 
expanding in incidence worldwide. Lung cancer is the most common cause of cancer-
related death in both men and women in the United States and it originates from different 
regions in the epithelial component of the airways. Malignant mesothelioma (MM) is 
relatively rare, but it is a very aggressive tumor of the cells that form the lining of the 
chest, heart and abdomen. Both malignancies differ in the incidence rate, however both 
are very aggressive and respond poorly to chemotherapy. Understanding the molecular 
mechanisms that underlie the pathogenesis of those deadly malignancies, as well as 
finding novel therapeutic strategies appears to be imperative.  
 
2.2. MOLECULAR PATHOGENESIS OF MALIGNANT MESOTHELIOMA 
MM is an aggressive tumor of the serosal lining of pleural (lungs and internal chest wall), 
pericardial (heart) and peritoneal (abdomen) cavities. MM is among the tumors with the 
shortest median survival after diagnosis, with little benefit provided by current 
chemotherapies (Carbone et al., 2002). MM arises after malignant transformation of 
human mesothelial cells (HM), and its pathogenicity has been traditionally linked to 
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environmental fibers exposure (asbestos and erionite; Gazdar et al., 2002). The 
mechanisms through which asbestos promotes cellular transformation are unclear, and 
may potentially involve: generation of reactive oxygen species (ROS) caused by asbestos 
exposure (Heintz et al., 1993); asbestos induced auto-phosphorylation of epidermal 
growth factor receptor (EGFR; Robledo and Mossman, 1999) or asbestos mediated 
immunosuppressive effects (Rosenthal et al., 1999). More recently, the DNA oncogenic 
virus SV40 has been linked to MM (Gazdar et al., 2002). SV40 oncogenic Tag was found 
to be expressed in some mesothelioma specimens in complex with p53 (Carbone et al., 
1997) and pRb protein family members (DeLuca et al., 1997). Expression of Tag in HM 
without cell lysis can lead to cellular transformation by mechanisms that involve 
inactivation of tumor suppressors, activation of pro-survival pathways including IGF-
1/IGF-1R (Porcu et al., 1994) and other mechanisms. SV40 appears to be required for 
MM cell growth and survival. Targeting Tag using antisense technologies in SV40-
positive MM cell lines caused cell growth inhibition and apoptosis (Weheed et al., 1999). 
Other evidences suggest an active role for SV40 in MM pathogenesis. SV40-positive 
MM display a characteristic inactivation of the tumor suppressor gene RASSF1A 
achieved through methylation of its promoter. Accordingly, progressive methylation of 
the RASSF1A promoter is one of the events promoted during the process of SV40-
mediated HM transformation (Toyooka et al., 2002). Furthermore, SV40 cooperates with 
asbestos in inducing MM in vitro and in vivo (Bocchetta et al., 2000; Kroczynska et al., 
2006) and exacerbates DNA damage caused by asbestos (Pietruska and Kane, 2007). The 
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presence of a MM epidemic in parts of Turkey suggests that genetic predisposition may 
also play a major role in MM onset (Carbone et al., 2007, Dogan et al., 2006).  
 
2.3. MOLECULAR PATHOGENESIS OF LUNG CANCER 
Lung cancer develops from normal bronchoepithelial cells through a multistep 
process that involves successive genetic and epigenetic changes that lead to inactivation 
of tumor suppressor genes, and/or activation of proto-oncogenes, and is usually 
associated with cigarette smoking (Sato et al., 2007).  
Some of the most important abnormalities in growth-stimulatory signaling 
pathways, which activate proto-oncogenes, work through deregulation of receptor 
tyrosine kinase (RTK) activity. Among those, over-expression of EGFR is found in the 
majority of NSCLC (Bunn and Franklin, 2002) and similarly another member of the 
ErbB RTKs HER2/neu is highly expressed in 30% of NSCLCs (Bunn et al., 2001). MYC 
phosphoprotein is amplified in 18-31% small cell lung cancers (SCLCs) and 8-20% in 
NSCLCs (Richardson and Johnson, 1993). Most oncogenic mutations in lung cancer are 
KRAS mutations (Sato et al., 2007), with RAS activating mutations found in 10-15% of 
NSCLCs, especially in ACL (Sekido et al., 2003). The catalytic subunit of 
Phosphatidylinositol 3-kinase (PI3K) is mutated in 3% of NSCLCs, and results in 
elevated kinase levels (Samuels et al., 2004). 
Signal Transducers and Activators of Transcription (STAT) family members 
STAT3 and STAT5 contribute to lung cancer by stimulating proliferation and inhibiting 
apoptosis through activation of transcription of the relevant genes (Karamouzis et al., 
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2007). NSCLCs with mutated EGFR show enrichment of STAT3 activation, which 
mediate oncogenic effects of mutant EGFR (Alvarez et al., 2006).  
Other important mechanisms that lead to lung cancer pathogenesis involve 
inactivation of major tumor suppressor genes including p53 and pRb. The transcription 
factor p53 is a protein that is stabilized in response to multiple stimuli including hypoxia, 
DNA damage and oncogenic stress. Activation of p53 leads to the expression of genes 
that are involved in cell cycle arrest or apoptosis (P21, BAX, PUMA etc.; Vousden and 
Lu, 2002). P53 is inactivated by mutation in 90% of SCLCs and 50% of NSCLC 
(Takahashi et al., 1989). Most inactivating mutations of P53 are point mutations (adducts 
at p53 critical residues) and to a lesser extent homozygous deletions, and are frequently 
caused by tobacco smoke carcinogens (benzo[a]pyrene; Hainaut et al., 1998). MDM2 is 
an important p53 regulator involved in its degradation by polyubiquitination and is 
amplified in 6% of NSCLCs, resulting in loss of p53 function (Higashiyama et al., 1997). 
p14
ARF
, which is another relevant p53 regulator, is lost in 65% of SCLCs and 40% of 
NSCLCs and is associated with the loss of p53 expression and activation (Gazzeri et al., 
1998; Vonlanthen et al., 1998).  Mutations in the gene coding for p14
ARF
 may result in 
deregulated expression of p16
INK4A
 which is derived from the same locus.  
Majority of lung cancers carry the mutation in one of the components of p16
INK4A
 
– cyclin D1 - CDK4 – pRb cell cycle regulatory pathway, which in turn causes abnormal 
functioning of its other components. In effect, majority of SCLCs have inactivated tumor 
suppressor gene pRb (found in almost 90% of SCLCs and only in 15-30% of NSCLCs; 
Reissmann et al., 1993) whereas p16INK4a, a protein that regulates pRb function and 
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keeps it in the tumor suppressor state, is frequently inactivated in NSCLCs (70%; 
Belinsky et al., 1998). Decreased activation of p16INK4a is due to homozygous deletion, 
mutation or promoter hypermethylation. pRb pathway can also be inactivated by 
overexpression of CDK4 (amplified in a subset of NSCLCs) or Cyclin D1 (overexpressed 
in 40% NSCLCs) by blocking the growth suppressive activity of p16INK4a (Sherr and 
McCormick, 2002).  
 
2.4. NOTCH SIGNALING 
Notch is an evolutionary conserved family of single transmembrane receptors that 
participate in the development of multicellular organisms by regulating the following 
critical processes: lateral inhibition, lineage specification and boundary formation 
(Radtke and Raj, 2003). To date, four Notch receptor paralogs (Notch 1-4) and five 
Notch ligands have been identified in mammals (Delta-like-1, Delta-like-3, Delta-like-4, 
Jagged-1 and Jagged-2; Lai 2004). Notch is synthesized as a single precursor protein, and 
during post-transcriptional processing in trans-Golgi becomes cleaved by furin-like 
proteases into heterodimer comprising of an extracellular domain (N
EC
) non-covalently 
associated with transmembrane domain (N
TM
; Fig. 2; Miele, 2006). N
EC
 contains multiple 
EGF-like repeats, whereas N
TM
 consists of extracellular ‘Lin-Notch’ repeats, a single-
pass transmembrane domain and an intracellular domain, the latter composed of 
‘RAM23’ (which participates in CBF-1/RBPJ! binding, see below), six ankyrin repeats 
and a polyglutamine stretch and a PEST region, possibly involved in ubiquitination 
(Nickoloff et al., 2003). Upon ligand binding N
EC
 dissociates from N
TM
, and becomes 
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endocytosed along with the ligand by ligand expressing, neighboring cells. This event 
activates cleavage of extracellular fragment of N
TM
 catalyzed by ADAM10 or ADAM17 
metalloproteases, followed by intracellular cleavage mediated by !-secretase (aspartyl 
protease; Brou et al., 2000). This second cleavage releases the intracellular fragment 
(N
IC
), which is able to translocate into the nucleus, where it binds CBF-1 and regulates 
transcription of its target genes (Miele, 2006). The mammalian member of CBF1-
Suppressor of Hairless-Lag1 (CSL) transcription factors CBF-1 binds to a consensus 
sequence cGtGGGAA and acts as a transcriptional repressor by binding to a corepressor 
complex that includes SMRT or N-coR, SKIP, CIR, HDAC, SHARP, CtBP and CtIP 
(Miele, 2006). N
IC
 binding to the CBF-1-corepressor complex replaces SMRT and 
histone deacetylase (HDAC) for transcriptional coactivators including mastermind like-1 
(MAML1) and histone acetyl transferases (HAT) and results in activation of target genes 
(Lai, 2004). The number of genes that are directly or indirectly regulated by Notch is 
large and depends on the cellular context. The most common are the bHLH (basic helix-
loop-helix) transcription factors families: HEY, HES (hairy/enhancer of split in 
Drosophila melanogaster) and HERP. Other Notch target genes include p21
Cip/Waf
, 
CyclinD1, CyclinA, transcription factors of the NF"B family, poly (ADP-ribose) 
polymerase and SKP2 ubiquitin ligase which triggers degradation of p27
Kip1
 (Sarmento et 
al., 2005). Some of the Notch transcriptional targets have been shown to be also MYC 
targets in primary human T-cell lymphoblastic leukemia and include genes that regulate 
cell growth (Palomero et al., 2006); in the same system cMYC itself is a direct target of 
Notch (Weng et al., 2006).  
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Figure 2. Notch signaling 
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Notch signaling is involved in many developmental events that are highly 
context-dependent. Notch activation determines cell fate by controlling responsiveness to 
either proliferative or differentiation stimuli, and allows for their proper interpretation. 
Depending on the conditions Notch can have differential effects on cell’s 
proliferation and apoptosis. Notch-1 promotes differentiation of keratinocytes (Nickoloff 
et al., 2002) and myeloid progenitor cells (Schroeder and Just, 2000). On the other hand, 
induction of Notch stimulates proliferation of mammary epithelial cells (Lee et al., 1999) 
and hematopoietic progenitor cells (Carlesso et al., 1999).  
 
2.5. NOTCH AND CANCER 
The oncogenic role of Notch was first identified in T-ALL (Reynolds et al., 1987) 
and is associated with chromosomal translocation resulting in deregulated expression of 
truncated form of Notch-1, which corresponds to N
IC 
(Radtke and Raj, 2003). Other 
studies showed that activating mutations of Notch-1 that stabilize N
IC
 or facilitate the 
cleavage of it are found in almost 80% of T-ALL (Mansour et al., 2007). There is an 
increasing evidence that aberrant Notch signaling plays a role in many cancers. 
Deregulated expression of Notch pathway components was demonstrated in other cancers 
of hematopoietic origin, like B-cell chronic lymphoid leukemia (B-CLL; Hubmann et al., 
2002), as well as in Hodgkin's and large cell anaplastic lymphomas (Jundt et al., 2002). 
Altered expression of Notch receptors and ligands was demonstrated in many solid 
tumors. Truncated, constitutively active Notch-1 and Notch-4 cause mammary tumors in 
mice (Callahan and Raafat, 2001; Dievart et al., 1999; Gallahan and Callahan, 1997) and 
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high expression of Notch-1 and Jagged-1 has been associated with poor prognosis in 
breast cancer (Reedijk et al., 2005). Overexpression of intact Notch receptors has been 
documented in cervical, pancreatic, endometrial, renal, lung, colon, head and neck 
carcinomas (Zagouras et al., 1995; Miele et al., 2006) and melanoma (Balint et al., 2005). 
A large line of evidence supports the role of Notch in contributing to tumor 
progression. However in certain types of cancer Notch has been shown to have a tumor 
suppressor function. Notch-1 induces growth arrest and promotes differentiation of 
keratinocytes in humans and mice (Nickoloff et al., 2002; Rangarajan et al., 2001). 
Overexpression of N
IC 
inhibits proliferation of myeloid progenitor cells (Schroeder and 
Just, 2000). In B cells apoptosis caused by N
IC
 expression is mediated through HES 
family of proteins, whereas growth arrest is mediated independently (Morimura et al., 
2000). Activated Notch-1 expression induces cell cycle arrest in SCLC by up-regulating 
cyclin-dependent kinase inhibitors WAF1 (p21) and KIP1 (Sriuranpong et al., 2001). 
However, since the effects of Notch signaling are strictly dose- and time-dependent, 
experiments with over-expressed active form of Notch could lead to artifacts and should 
be interpreted bearing this caviat in mind. Our results in ACL cell lines reveal that the 
effects of Notch signaling depend on oxygen concentration (Chen et al., 2007). We found 
that in normoxic environment Notch-1 suppresses growth, whereas under low oxygen 
concentration Notch-1 promotes survival of ACL cells. Thus, when studying biological 
functions of Notch signaling in cancer, many variables need to be considered including 
dose, time and environment. 
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2.6. NOTCH IN MALIGNANT MESOTHELIOMA 
 Increasing number of reports indicate oncogenic role of Notch in solid tumors. 
The role of Notch signaling in MM is poorly understood. Notch-1 expression is elevated 
in MM biopsies as compared to stromal tissue. Notch-1 is required for the maintenance of 
Simian Virus 40 (SV40) transformed phenotype of HM, and inhibition of Notch-1 
resulted in SV40-transformed HM cell growth arrest (Bocchetta et al. 2003). Expression 
of Notch-1 in those cells is regulated primarily by small tumor antigen (tag), which 
inactivates protein phosphatase 2A (PP2A; Testa and Giordano, 2001), resulting in an 
increased phosphorylation of the components of the ERK pathway. There are no reports 
indicating the role of Notch signaling in MM that is independent of SV40. 
 
2.7. NOTCH IN LUNG CANCER 
Over-expression of Notch-1
IC 
caused growth arrest of SCLC cell lines 
(Sriuranpong et al., 2001). Hence, this study suggested a tumor suppressive role in SCLC. 
Three studies proposed an oncogenic role for Notch-3 in NSCLC. Dang et al. (2000) 
found a chromosomal translocation t(15;19) in an aggressive lung carcinoma. Similar 
translocations were found in two separate thoracic malignancies case reports (Kees et al., 
1991; Lee et al., 1993) including a thymic carcinoma (Kubonishi et al., 1991). The likely 
gene to be affected by such translocation was proposed to be Notch-3 because the 
NSCLC cell line HCC2429  (harboring such translocation) expressed high levels of the 
Notch-3 mRNA (Dang et al., 2000). Moreover, 7 out of 44 NSCLC cell lines expressed 
the Notch-3 mRNA as determined by Northern blot hybridization (Dang et al., 2000). 
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The Dang group further expanded on these early findings. The expression of a 
truncated Notch-3 receptor (missing the intracellular portion of the protein, and therefore 
considered as a Notch-3 dominant negative form) caused reduced growth of NSCLC cells 
and increased “growth factor dependence” (Haruki et al., 2005). In a more recent study, 
treatment of NSCLC cell lines with a GSI (MRK-003) reduced tumor formation in 
xenografts mouse models. When Notch-3 was genetically inhibited through RNA 
interference, the same cells became GSI insensitive, indicating that Notch-3 was the 
target of the GSI used (Konishi et al., 2007). These results, and their interpretation, are 
somewhat controversial. In Haruki et al. (2005) the authors have not explored the 
possibility that the truncated, dominant negative Notch-3 over-expressed in their NSCLC 
cells could have saturated the cell membrane with a non-functional Notch receptor, 
ultimately resulting in the expression of a Notch pan-inhibitor. This possibility is 
reinforced by the fact that the authors did not verify that in their experimental conditions 
activation of Notch-1, -2 and -4 was still attainable. The study of Konishi et al. (2007)
 
is 
also difficult to interpret. The authors propose an oncogenic role for Notch-3 in NSCLC.  
However, when Notch-3 was down-regulated genetically, NSCLC cells grew and formed 
tumors. If Notch-3 was the main oncogene in NSCLC cells, Notch-3 siRNA should have 
yielded similar effects as dominant negative Notch-3 and chemical inhibition. Therefore 
it does not seem to be the case that the role of Notch-3 in NSCLC is yet well understood. 
A recent study (Zheng et al., 2007)
 
showed that forced expression of constitutively active 
Notch-1 inhibited growth of the ACL line A549 cultured in standard conditions and 
interfered with tumor growth in vivo.  We obtained analogous results in the same cell line 
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cultured in normoxia (Chen et al., 2007). However, experiments generated from 
Notch-1 over-expression are difficult to interpret and may lead to artifactual results. 
Dissimilar conclusions drawn by Zheng et al. (2007)
 
were proposed by a Chinese study 
based on immunohistochemical analysis of NSCLC tumor biopsies compared to normal 
“bronchi mucosa” (Jiang et al., 2007). These authors observed strong Notch-1 
immunoreactivity in NSCLC compared to normal lung, which correlated with Jagged-1 
and VEGF expression. The intensity of the immunostaining appeared to increase with 
more advanced tumor stages. This was not observed in the study by Chen et al. (2007) 
performed on snap-frozen tissue samples. In conclusion, a better understanding of the 
role played by Notch receptors in lung cancer still awaits further study.   
 
2.8. NOTCH AND HYPOXIA 
 Due to the high cell expansion and insufficient neo-vascularization, solid tumors, 
including MM and lung cancer, are highly hypoxic. Rapid proliferation of tumor cells 
requires increased glucose metabolism. The lack of oxygen shifts glucose metabolism 
from oxidative phosphorylation to anaerobic glycolysis, which results in accumulation of 
pyruvate and lactate. Tumor cells adapt to the hypoxic microenvironment by inducing the 
expression of genes that promote cell survival, motility and angiogenesis (Keith and 
Simon, 2007). Hypoxia Inducible Factor-1" (HIF-1") is the major transcription factor 
responsible for regulation of expression of genes under hypoxia. Genes that are directly 
regulated by HIF-1" include:  Erythropoetin (EPO), Vascular Endothelial Growth Factor 
(VEGF), and Inducible Nitric Oxide Synthase (iNOS; Gordan and Simon, 2007). Under 
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normoxic conditions HIF-1" becomes degraded by ubiquitin mediated proteasomal 
pathway. Under hypoxia HIF-1" is stabilized and can promote tumor progression. In B 
progenitor cells forced expression of Notch leads to acute lymphoblastic leukemia (Pear 
and Aster, 2004). In many cell types, including neuronal progenitors, hypoxia relies on 
Notch to maintain the undifferentiated state. Hypoxia promotes Notch-1 stabilization and 
induces transcription of Notch responsive genes by recruiting HIF-1" to the target gene 
promoters (Gustafsson et al., 2005). These findings suggest that oxygen concentration is 
an important determinant of Notch function, and needs to be accounted for in studying 
Notch signaling pathways in MM and lung cancer. 
 
2.9. IGF-1R PATHWAY 
 The insulin like growth factor-1 (IGF-1) signaling pathway is a complex system 
involved in regulation of processes that lead to cell growth, proliferation and 
development. Uncontrolled transduction of signals through IGF-1R may result in 
pathological conditions including transformation, metastasis and evasion of apoptosis. 
The IGF-1R system is composed of IGF-1 ligands (IGF-1, IGF-2), transmembrane 
receptors (IGF-1R, IGF-2R and insulin receptor-IR) composed of " and # subunits, and 
IGF binding proteins (IGFBPs) which affect bioavailability of IGFs in extracellular fluids 
(LeRoith and Roberts, 2003). Upon ligand binding to the extracellular domain of the 
receptor, conformational change of the receptors occurs, which leads to the auto-
phosphorylation of the receptor’s tyrosine residues on the # subunit. This, through 
docking molecules such as members of the insulin receptor substrate (IRS) family (IRS-
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1, IRS-2, IRS-3, IRS-4) and or Src homology 2 domain containing transforming 
protein (SHC), results in activation of either PI3K or mitogen activated protein kinase 
(MAPK) pathways. PI3K is a major downstream effector of RTKs. It is a lipid kinase, 
and catalyzes the phosphorylation of PIP2 to form phosphatidylinositol-3,4,5-
triphosphate (PIP3). PIP3 is a second messenger at the plasma membrane where it 
recruits Akt-1 (serine-threonine protein kinase, protein kinase B; Cantley, 2002). This 
event ultimately leads to activation of downstream effectors, and expression of target 
genes that mediate the proliferative and anti-apoptotic effects of IGF-1 induced Akt-1 
signaling (LeRoith et al., 1995). The major supressor of the Akt-1 pathway is a lipid 
phosphatase PTEN, which dephosphorylates PIP3 to PIP2 at the plasma membrane to 
prevent the recruitment of Akt-1, and progression of the proliferative signal.  
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CHAPTER 3 
THE SV40 LARGE T ANTIGEN REGULATES IGF-1 EXPRESSION IN 
TRANSFORMED MESOTHELIAL CELLS 
 
ABSTRACT 
During SV40 mediated malignant transformation of human mesothelial cells 
(HM), oncogenic viral antigen Tag promotes cell proliferation by interfering with pro-
survival and tumor suppressive pathways. Tag is found in complex with p53, and the 
current view is that those complexes are the way to sequester and inactivate cellular p53. 
On the other front, Tag promotes cell survival by inducing insulin like growth factor-1 
(IGF-1) signaling which leads to cell proliferation. Using primary human cells and SV40-
transformed human cells, we show that in addition to inactivating p53 tumor suppressor 
activities, the Tag-p53 complex has growth stimulatory activities that are required for 
malignant cell growth. We found that in human cells, Tag/p53 complexes regulate 
transcription of the IGF1 gene by binding to the IGF1 promoter together with pRb and 
p300. Depletion of p53 leads to structural rearrangement of this multi-protein complex, 
resulting in IGF1 promoter transcriptional repression and growth arrest. Our data provide 
a novel mechanistic and biological interpretation of the p53/Tags complexes and of DNA 
tumor virus transformation in general. In the model we propose, p53 is not a passive 
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inactive partner of Tag. Instead thep53/Tag complex promotes malignant cell growth 
through its ability to activate the IGF-1 signaling pathway. 
 
INTRODUCTION 
IGF-1 pathway plays a critical role in regulating normal cell growth and 
transformation events. IGF1R
-/-
 mice are less than half the size of normal counterparts at 
birth and are viable for only a few hours (Liu et al., 1993). Mice lacking insulin receptor 
substrate-1 (IRS-1) are severely growth impaired, although being viable and reaching 
fertility (Araki et al., 1994; Tamemoto et al., 1994). 
In malignant setting IGF-1R is frequently over-expressed, and it functions as a 
potent anti-apoptotic agent supporting cell survival of neuronal, hematopoietic and 
fibroblast cells, to the point that IGF-1R signaling is commonly referred to as “cell 
survival factor” (Gluckman et al., 1992; Rodriguez-Tarduchy et al., 1992; Harrington et 
al., 1994). IGF-1R is absolutely required for the successful transformation of a number of 
cell lines (reviewed in Baserga, 1995). Furthermore, fibroblasts obtained from IGF1R
-/-
 
mice are virtually resistant to cell transformation operated by a variety of chemical 
carcinogens, as well as viral and cellular oncogenes (Sell et al., 1994). SV40 mediated 
cell proliferation requires the interaction of IGF-1 with its receptor (Porcu et al., 1992). 
Intact IGF-1R is required for SV40 mediated transformation of primary HM (Sell et al., 
1993). Tag can promote cell cycle progression in BALB/c 3T3 cells cultured in low 
serum only when IGF-1/IGF-1R pathway is active (Valentinis et al., 1994).   
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During malignant transformation DNA viral oncoproteins can bind and 
inactivate p53 tumor suppressor functions (Tag of human polyomaviruses JCV, BKV and 
SV40, the E1b of adenoviruses; Ali and DeCaprio, 2001). This allows infected cells to 
survive, and prevent p53-mediated apoptosis or cell growth arrest. Inactivation of p53 
impairs DNA repair thus favoring the early steps of carcinogenesis. The latter effect is 
mediated mostly by the ability of p53 to induce p21 expression, a CDK inhibitor that in 
turn causes cell cycle arrest, allowing DNA repair to take place. By inducing p21 
expression, p53 prevents cells that have accumulated genetic damage from undergoing 
mitosis and propagating the damaged DNA to the progeny. Due to its critical role in 
regulating the cell cycle, and DNA damage, which results in proper cell growth, cancer 
cells need to find ways to inactivate wild-type p53. Accordingly, inactivation of p53 must 
occur to transform primary cells in vitro (Hahn et al., 1999). Oncogenic viruses other 
than SV40 have developed unique mechanisms for inactivating p53; HPV16 oncoprotein 
E6, binds to cellular p53 promoting its ubiquitylation and degradation (Wernes et al., 
1990; Scheffner et al., 1990).  
The current hypothesis is that, upon Tag binding, p53 loses its ability to work as a 
transcription factor and as a tumor suppressor gene (Bargonetti et al., 1992; Jiang et al., 
1993; Segawa et al., 1993). A few studies have shown, however, that Tag in complex 
with p53 does not prevent p53 from binding to its DNA binding sites (Long et al., 1995; 
Sheppard et al., 1999; Technau et al., 2001). Moreover, p53 complexed with Tag was 
able to stimulate transcription of a p53-regulated promoter in cell free extracts from 
monkey and human cells (Sheppard et al., 1999). SV40-mediated transformation of 
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fibroblasts was enhanced by wild type mouse p53 (Michalovitz et al., 1986). Similarly, 
transformation of rat fibroblasts required both Tag and stabilized p53 (Deppert et al., 
1989). Animal studies have shown that SV40 is more efficient in promoting tumor 
growth in the presence of wild type p53 (Herzig et al., 1999). These data did not fit with 
the generally accepted view that the major role of DNA viral Tags is to bind to and 
inhibit cellular p53.  
Primary HM have high levels of p53, and in such environment SV40 requires 
IGF-1R signaling for cellular transformation. Here we investigated the possible 
biological effects of Tag-p53 complexes on IGF-1/IGF-1R pathway mediated cell growth 
and transformation.  
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MATERIALS AND METHODS 
 
CELLS AND GENE TRANSFER PROCEDURES 
Primary human mesothelial cell (HM) cultures were obtained from non-cancerous 
donors, cultured and characterized as described in Bocchetta et al. 2000. These cells 
contain wild-type p53 (Bocchetta et al., 2000). SV40-transformed HMs (S-HML) were 
obtained through HM infection with SV40 virions (10 plaque forming units –pfu/cell). 
Six to eight weeks after infection tridimensional foci of transformed cells were hand 
picked and cultured into cell lines. The latter were grown in DMEM supplemented with 
5% fetal bovine serum (FBS). Critical results were confirmed in three independent S-
HMLs.  
Retroviral packaging was performed with Phoenix cells using standard 
procedures. S-HML transduced with the retrovirus expressing the tetracycline regulator 
(TR; TET-ON system, Clontech Laboratories Inc., Mountain View, CA) were selected 
using 600 µg/ml of G418. After selection, the functionality of the system was assayed as 
recommended by the manufacturer. These cells were transduced with the retrovirus 
expressing HPV16 E6 (in the presence of doxycycline). Transduced cells were then 
selected with 600µg/ml of hygromycin and the resulting clone was named S-HML/E6.  
Western blot and immunostaining experiments were performed as described in 
Bocchetta et al. 2000.  
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DNA SYNTHESIS ANALYSES 
Detection of proliferating cells by the measurement of the DNA replication was 
performed using the 5-bromo-2'-deoxyuridine (BrdU)
 
Flow kit (BD PharMingen, 
Franklin lakes, NJ) according to the manufacturer’s
 
instructions. Briefly, 1 x 10
6
 cells 
were stimulated with
 
IGF-1 (5 nM) in culture medium. A total of 100 $l of BrdU solution
 
(1 mM BrdU in PBS) was added to each dish containing 10 ml culture medium and was 
incubated for 8 hours at 37°C. The cells were then fixed and permeabilized
 
with 
Cytofix/Cytoperm buffer (BD PharMingen). To prevent cells form clumping (which 
would interfere with FACS analysis) the cellular DNA
 
was digested with DNAse for 1 h 
at 37°C. The cells were
 
stained with an anti-BrdU FITC-conjugated antibody and 
analyzed by FACSCanto Flow Cytometer (BD Bioscience, San Jose, CA). Cells that 
stained positively for BrdU indicated actively proliferating ones.  
Apoptosis was assayed using Annexin V/7-aminoactinomycin D staining 
according to standard procedures. 
 
RNA STUDIES 
Nuclear run-on assays were performed as described in Bocchetta et al. 2003. Each 
slot of alkali-denatured probes contained 5 µg of probe DNA, which corresponded to: a 
133 bp PCR fragment of the human 18S rRNA gene; a 654 bp PCR fragment of the 
human p21 cDNA; a 378 bp PCR fragment of the human Bax cDNA; a 593 bp PCR 
fragment of the human IGF1 cDNA; # phage DNA digested with Hind III. After 
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hybridization to 
32
P-labelled nuclear transcripts, membranes were washed and exposed 
to both X-ray film and a phosphoimager. 
RT-Real time PCR was performed using standard protocols. Briefly, cells were 
dissociated with trypsin/EDTA, harvested, and snap frozen. Total cellular mRNA was 
obtained using the RNeasy kit (Qiagen, Valencia, CA) in the presence of RNAse-free 
DNAse I. The concentration of RNA in each sample was measured using 
spectrophotometer (GE Healthcare, Uppsala, Sweden), and the quality of the mRNA was 
assayed in 1% formaldehyde agarose gels. Two µg of total RNA from each sample was 
reverse transcribed using a first strand synthesis kit (MBI-Fermentas, Hanover, MD) in 
the presence of 10 pmol of random primers. Real Time PCR was performed as follows: 
1/5 of the reverse transcription reaction from each sample was diluted serially in H2O to 
determine the optimal range of dilution for the samples (CT between 15 and 25), using a 
Gene Amp 5700 (PE-Applied Biosystems, Wellesley, MA). Oligo pair combinations (see 
Table 2) were chosen using the Primer Express 1.0 software (Applied Biosystems). 
Reactions were performed using the SYBR GREEN PCR Master Mix (Applied 
Biosystems). After estimating the sample with higher levels of GAPDH mRNA, 1:2 serial 
dilutions were made in H2O (range 1 to 128) to construct a calibration curve for each 
mRNA. Similar calibration curves were run along with each experiment. “No reverse 
transcription” of each sample was run as the negative control. mRNA values were 
normalized for GAPDH amounts, and plotted as a percentage of the control sample. 
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Reporter assays were performed using the Dual-Glow Luciferase Assay system 
(Promega, San Luis Obispo, CA) and measured with a luminometer (Veritas; Turner 
Biosystems, Sunnyvale, CA). 
 
CHROMATIN IMMUNOPRECIPITATION ASSAYS 
Crosslinking of 1 x 10
7
 cells was performed for 10 mins at a room temperature 
using 1% formaldehyde in PBS. The reaction
 
was stopped, by adding 0.25
 
M glycine in 
PBS. The cells were harvested and the DNA was sheared by sonication in lysis buffer (20 
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% NP-40) supplemented with 1% SDS, using a 
Branson SONIFIER 250 (Wolf Laboratories Lmd, UK) to
 
generate DNA fragments $600 
bp. Cell lysates were diluted ten times with lysis buffer to reduce the SDS final 
concentration to 0.1%. Lysates were precleared with protein A/G agarose beads (Pierce, 
Rockford, IL) for 4 hr
 
at 4°C, and were then incubated overnight at 4°C with the 
respective primary
 
antibodies. Immune
 
complexes were collected on Protein A/G agarose 
beads overnight at 4°C. Samples were dialyzed twice against dialysis buffer (2 mM 
EDTA pH 8.0, 50 mM Tris-HCl pH 8.0). Following 4 washes in 1 ml wash buffer (100 
mM Tris-HCl pH 8.0, 500 mM LiCl, 1% NP-40); immune complexes were eluted
 
from 
the beads by vigorously shaking twice for 15 minutes in 150 µl of 50mM NaHCO3, 1% 
SDS. Cross-linking
 
was reversed by incubation in 0.15 M NaCl overnight at 65°C.
 
Each 
sample’s DNA was ethanol precipitated and purified using QIAprep spin miniprep kit 
(Qiagen).
 
DNA was resuspended in 100 µl of TE buffer. Finally, each sample was PCR 
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amplified using appropriate oligonucleotides as primers (Table 2), and the results were 
visualized on 2% agarose gels. 
 
ANTIBODIES 
Target Type Company 
HPV16 E6 Ab-1 mouse monoclonal EMD Bioscience 
anti Xpress mouse monoclonal Invitrogen 
IGF-1R 2C8 mouse monoclonal Santa Cruz Biotech 
IGF-1 H-70 rabbit polyclonal Santa Cruz Biotech 
p300 H-272 rabbit polyclonal Santa Cruz Biotech 
p300 D-12 mouse monoclonal Santa Cruz Biotech 
Tag pAb419 mouse monoclonal Santa Cruz Biotech 
p53 DO-1 mouse monoclonal Santa Cruz Biotech 
pRb IF-8 mouse monoclonal Santa Cruz Biotech 
mdm2 D-12 mouse monoclonal Santa Cruz Biotech 
P21 187 mouse monoclonal Santa Cruz Biotech 
GAPDH MAB374 mouse monoclonal Chemicon 
 
         Table 1. A list of all antibodies used in Chapter 3 
 
Annexin V PE-conjugated was from BD Biosciences (Franklin Lakes, NJ). 
Agarose-conjugated protein A/G was from Pierce (Rockford, IL). 
!    
 
29!
PLASMIDS 
HPV16 E6 was PCR amplified from pE6E7 (Dr Martin W. Kast, University of 
Southern California, CA) and ligated into different plasmids. The constructs used here 
were the following: pE6CDNA4, in which E6 was cloned into the Kpn I/Not I sites of 
pcDNA4/HisMax (Invitrogen); pREVE6, in which the recombinant E6 obtained after the 
construction of pE6cDNA4 was PCR amplified and cloned into the Hind III/Cla I sites of 
pREV-TRE (Clontech Laboratories, Mountain View, CA). In retroviral transduction 
experiments the Tet-On Gene Expression System (Clontech) was used. It included pTet-
ON, encoding the tetracycline transactivator, pTRE-d2EGFP, used to validate the 
functionality of the TET-ON clones, and pREV-TRE, which expresses proteins under the 
control of a CMV minimal promoter that contains four tetracycline responsive elements. 
All vectors can be used as ordinary plasmids, or they can be packaged in retroviral 
particles. pSmaBgl-LUC was provided by Dr Renato Baserga (Kimmel Cancer Center, 
PA). pMDM2 was provided by Dr Zhuo Zhang (University of Alabama, AL). pGRI5, 
expressing wild type human IGF1R under the control of a CMV promoter was a gift from 
Dr Clodia Osipo (Loyola University Chicago, IL). p53mt135, expressing dominant 
negative p53 was purchased from BD Biosciences. Oligonucleotides 
5’GATCCCGCAATGGTTCACTGAAGACCCAGGTCCAGAGAAGCTTTCTGGACC
TGGGTCTTCAGTGAACCATTGTTTTT-3’and 5’CTAGAAAAACAATGGTTCACT 
GAAGACCCAGGTCCAGAAAGCTTCTCTGGACCTGGGTCTTCAGTGAACCATT
GCGG-3’ were annealed in 20 mM Tris-HCl pH 7.4, 1 mM EDTA pH 8.0, 100 mM 
NaCl by incubating 2 nmoles of each primer at 100°C for 5’. The reaction was then left 
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to slowly cool down to room temperature in a heat block. Annealing was verified by 
running the products before and after annealing onto a 10%, non-denaturing 
polyacrylamide gel. The annealed products were ligated into the Bam HI and Xba I sites 
of pGE-1 (Gene Eraser, Stratagene, La Jolla, CA) to give rise to plasmid shp53. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
           Table 2. A list of oligonucleotides used in Chapter 3 
 
Gene Primer Sequence 
P21-A 5’-CCTGCCGAAGTCAGTTCCTTG- 3’ 
P21-B 5’- GCGGCAGACCAGCATGACAG -3’ 
P21-C 5’- AAACTGAGACTAAGGCAGAAGATGTAGAGC -3’ 
Bax-A 5’- ATGGACGGGTCCGGGGAGC -3’ 
Bax-B 5’- GCAGAGGATGATTGCCGCCG -3’ 
Bax-C 5’- GCACAGGGCCTTGAGCACCA -3’ 
GAPDH-F 5’- CAATGACCCCTTCATTGACC -3’ 
GAPDH-R 5’- TTGATTTTGGAGGGATCTCG -3’ 
IGF-1 A 5’- CTTCTGTTTGCTAAATCTCACTGTC -3’ 
IGF-1 B 5’- TTTTATTTCAACAAGCCCACAGGG -3’ 
IGF-1 C 5’-GGGCTGATACTTCTGGGTCTTGG-3’ 
MDM2-F 5’- GATCCTGGAAGTGTCCCTGA-3’ 
MDM2-R 5’- AAGGACCGTTCTGTTTGTGG-3’ 
18S F 5’-TGATTAAGTCCCTGCCCTTTGT-3’ 
18S R 5’-TCAAGTTCGACCGTCTTCTCAG-3’ 
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p21: Primers A and C were used to amplify a 654 bp fragment used as probe in nuclear 
run-on experiments, while primers B and C were used in RT-Real time experiments 
(positions 504-654 of the p21 cDNA). 
Bax: Primers A and C were used to amplify a 378 bp fragment used as probe in nuclear 
run-on experiments, while primers B and C were used in RT-Real time experiments 
(positions 228-378 of the Bax cDNA). 
IGF-1: Primers A and C were used to amplify a 593 bp fragment used as the probe in 
nuclear run-on experiments, while primers B and C were used in RT-Real time 
experiments (positions 393-593 of the IGF1 cDNA). 
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OLIGONUCLEOTIDES USED IN CHIP ASSAYS 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. A list of oligonucleotides used for ChIP experiments on the  
                     IGF-1 promoter 
 
Region Primer sequence Position 
A-F 5’-
 
GGTACCCCAAAGCCTCTCATG-3’ -1952 to -1700 
A-R 5’- CCCAACTACAACATCCCTAGG-3’ -1952 to -1700 
B-F 5’-GCCCCTGAAGGGACTTGACC-3’ -1764 to -1414 
B-R 5’-GACTCTCAGGGGACTGACAC-3’ -1764 to -1414 
C-F 5’-CCAGAGTAGGATTTCAAGCAG-3’ -1472 to -1078 
C-R 5’-CTGGCTAGCAATACCCTCTTG-3’ -1472 to -1078 
D-F 5’-AGAACCGTGAATTCTCAATGGC-3’ -1215 to  -921 
D-R 5’-GCAAACAATTTTCCTGTTGTTTG-3’ -1215 to  -921 
E-F 5’-CTGGCACACAGACTCCCTCTG-3’ -1031 to -659 
E-R 5’-GGAAGACAGCACTCGGGTGAC-3’ -1031 to -659 
F-F 5’-ACCAATCCAATGCTGCCTGCC-3’ -757 to -464 
F-R 5’-TTTCTGCTGGGCATGAAGACAC-3’ -757 to -464 
G-F 5’-TAGAATCTAAAATTGCTCTC-3’ -555 to -322 
G-R 5’-AAATAACATCATACCTTTGC-3’ -555 to -322 
cont-F 5’-CAGTCTTCTGTGTCCTGTTC-3’ N/A 
cont-R 5’-AGAGGCTGATGGGAAGGAAC-3’ N/A 
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IGF1 was artificially downregulated using Hs_IGF1_5_HP Validated siRNA (Qiagen). 
The negative control for ChIP assays was a 266 bp region (part of BAC RP11-25I15, 
locus AC089982, a sequence far from known genes located on chromosome 12q12, while 
the IGF1 gene is located on chromosome 12q22). 
 
 
RESULTS 
 
S-HML/E6 CELLS EXPRESS FUNCTIONALLY ACTIVE RECOMBINANT HPV16 E6 
S-HM are characterized by high levels of endogenous p53. We wanted to study 
the effects of lowering p53 in cells expressing the SV40 Tag. To achieve this goal, we 
expressed HPV16 E6, an oncoprotein which binds and targets p53 for ubiquitin mediated 
degradation (Wernes et al., 1990; Scheffner et al., 1990) in S-HML. We used a stable, 
tetracycline inducible transduced cell clone expressing a fusion protein consisting of 6 
histidines at its N-terminal portion (for conjugation to Ni-charged carriers), an Xpress 
peptide flag and the full length HPV16 E6. These cells (named S-HML/E6) express the 
SV40 Tag and upon doxycycline treatment also expressed HPV16 E6 that bound and 
degraded p53 (Fig. 3 and Fig. 4).  
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Figure 3. E6 induction down-regulates p53 and p53 regulated gene products. (A) 
Expression of Tag and p53 in S-HML expressing E6 (which degrades p53, Fig.4). (B) 
Reduced p53 expression is paralleled by decreased p21 and mdm2 expression. Cells were 
treated with or without doxycycline for 48 hr to induce E6 expression. E6: S-HML/E6 
cells. CONT: control cells. (C) Transient transfection of S-HML with pE6CDNA4 causes 
marked p53 downregulation. C24: control 24 hr after transfection; E624: E6 24 hr after 
transfection; C48: control 48 hr after transfection; E648: E6 48 hr after transfection. 
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DECREASED AMOUNTS OF P53 IN S-HML/E6 CORRESPOND WITH DECREASED 
EXPRESSION OF PROTEINS TRANSCRIPTIONALLY REGULATED BY P53 AND CAUSE CELL 
GROWTH ARREST 
We measured p53 and Tag expression levels at different time-points after 
doxycycline induction in S-HML/E6 cells. 48 hr after doxycycline-mediated induction of 
HPV16 E6, S-HML/E6 had reduced protein expression of p53, and is followed by the 
reduction in expression of its targets p21 and mdm2 (Gudkov and Komarova, 2003). Tag 
expression was not influenced by doxycycline treatment (Fig. 3A, B). We hypothesized 
that these effects could have caused apoptosis/mitotic catastrophe, or a proliferative 
advantage. Instead, Annexin V/ propidium iodide (PI) staining followed by FACS 
analysis did not show evidence of apoptosis or the appearance of aberrant DNA peaks (an 
indication of mitotic catastrophe), and S-HML/E6 showed a doxycycline, dose-dependent 
reduction in DNA synthesis as compared to controls (Fig. 4A). Since doxycycline has 
pleiotropic effects that might have influenced these findings, we expressed recombinant 
E6 protein in transiently transfected S-HML. We obtained identical results: E6-
transfected S-HML had undetectable p53, and were growth arrested as compared to 
controls (Fig. 3C and Fig. 4B). The reciprocal experiments (growth curves for the 
inducible system and DNA incorporation assay for S-HML transiently transfected with 
E6) gave identical results (Bocchetta et al., 2008). To understand why depletion of 
cellular p53 in S-HML resulted in growth arrest, we investigated genes that are 
transactivated by Tag (Chen et al., 1996, Porcu et al., 1994). We found no variation in 
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cdc2 protein expression after doxycycline treatment of S-HM/E6, while the same 
treatment virtually abolished IGF-1 precursor and IGF-1R expression (Fig. 4C). 
 
 
 
Figure 4. E6 induction in S-HML suppresses DNA synthesis and causes cell growth 
arrest. Critical components of the IGF-1 signaling pathway are downregulated upon 
either E6 or mdm2 induction. (A) Bromodeoxyuridine (BrdU) incorporation assay 
conducted on control cells (squares) and SV40 transformed human mesothelial cells 
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transfected with plasmid expressing E6 (S-HML/E6; bullets) performed at increasing 
doxycycline concentrations. The histogram is the average of 4 independent experiments; 
each measurement was determined on 30,000 events. The percentages of DNA 
incorporation of ES-HML/E6 versus control cells were (at concentrations of doxycycline 
in µg/ml): 0, 62.78 ± 24.40%; 0.1, 55.00 ± 16.67%; 0.4, 37.22 ± 11.11%; 1.0, 22.44 ± 
13.33%. The apparent lowered DNA incorporation measured in S-HML/E6 versus 
control cells at 0 µg/ml of doxycycline may be explained by “leaky” transcription at the 
“tet-on” retroviral promoter. (B) Cell growth curves of S-HML transfected with a control 
plasmid (pcDNA4/His-Max; squares) and with the same plasmid expressing recombinant 
E6 (bullets). The histogram is the average of three independent experiments. Using a 
plasmid expressing green fluorescent protein followed by FACS analysis we determined 
that the efficiency of transfection was > 95% (using electroporation). (C) Western blot 
analysis performed in S-HML/E6 and control cells in the presence and absence of 
doxycycline. Representative experiment. Western blot was performed 48 hr after 
antibiotic exposure (+ lanes). E6: S-HML/E6. (D; Top) Western blot analysis performed 
on HM transfected with the control plasmid (“cont” lane) or with the plasmid expressing 
recombinant E6 (“E6” lane). (D; Bottom) Western blot analysis conducted on S-HML 
transfected with a control plasmid (“cont” lanes) and with a plasmid expressing human 
mdm2 (mdm2 lanes). Note mdm2 expression and downregulation of p53, p21, IGF-1 and 
IGF-1R.  
 
 
The effects observed upon E6-transfection appeared to be dependent on the presence of 
Tag, because E6-transfection of primary HM (which do not contain SV40) caused the 
opposite effect: a 4.3 fold increase of IGF-1 expression (Fig. 4D; Top). Since E6 did not 
influence Tag expression but influenced p53 expression in S-HML (Fig. 3A) we 
speculated that the E6 activities in Tag containing cells were mediated through the 
degradation of p53. To test our hypothesis that the decreased expression of p21, mdm2, 
IGF-1 and IGF-1R upon E6 induction was related to p53 down-regulation, we 
deregulated p53 in S-HML using a shRNA against p53, a dominant negative p53 
(p53mt135, which interferes with proper p53 complex formation; Fig 5A and 5B, 
respectively) or over-expressing mdm2 in S-HML (Fig. 4D; Bottom): all these 
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approaches yielded reproducible p21, IGF-1 and IGF-1R down-regulation. The most 
effective and reproducible way to down-regulate p53 expression in S-HML was 
expressing HPV16 E6 in these cells (Fig. 3C). Combined together, these results 
suggested that the decreased expression of p21, IGF-1 and IGF-1R was related to p53 
depletion independently of how it was achieved. 
                                 
Figure 5. Both p53 down-regulation through RNAi and transfection of S-HML with 
dominant negative p53 cause reduced expression of p21, mdm2, IGF-1 and IGF-1R. 
(A) Western blot analysis of the indicated gene products after transfection of S-HML 
with the plasmid encoding shp53. (B) Western blot analysis of the indicated gene 
products after transfection of S-HML with the plasmid encoding dominant negative p53. 
!
 
E6-MEDIATED P53 DOWN-REGULATION CAUSES S-HML CELL GROWTH ARREST THROUGH 
THE IGF-1/IGF-1R SIGNALING PATHWAY 
To confirm that p53 depletion in S-HML causes cell growth arrest through IGF-
1/IGF-1R signaling, we designed the experiment summarized in Fig. 6A.  
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Figure 6. E6-mediated inhibition of DNA synthesis in S-HML is mediated through 
the IGF-1/IGF-1R pathway. 1%, cells grown in 1% FBS; IGF-1, cells grown in 1% 
FBS plus IGF-1. (A) Schematic of the experiment performed to verify the hypothesis that 
E6-mediated impairment of DNA synthesis in S-HML is exerted through the IGF-1 
signaling pathway. (B) BrdU/FACS analysis performed on 1Cc cells grown in 1% FBS 
containing medium (red graph) or grown in medium supplemented with 1% FBS and 5 
nM IGF-1 (blue graph). Note that IGF-1 can resume DNA synthesis in these cells. (C) 
Same as in (B) performed on 1C6 cells. Note that these cells are unable to respond to 
IGF-1 stimulation. (D) Same as in (B) performed on 1R6 cells. Note that forced 
expression of the IGF-1R resumes the ability of S-HML to respond to IGF-1 stimulation. 
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S-HML were transfected with a plasmid expressing the IGF-1R under the control of a 
CMV promoter (1R cells). S-HML transfected with the empty plasmid served as control 
(1C cells). Both 1R and 1C cells were transfected in parallel with either the E6 expressing 
plasmid (yielding either 1R6 or 1C6 cells) or with the control plasmid for E6 (yielding 
either 1Rc or 1Cc cells). 24 hr after transient transfection cells were cultured in 1% FBS, 
or in 1% FBS supplemented with 5nM of purified IGF-1. 48 hr after transient transfection 
all cells were analyzed for DNA synthesis using BrdU incorporation assay/FACS 
analyses (Fig. 6 B-D). Both 1Rc and 1Cc (these cells do not express E6 and have normal 
p53 amounts) were able to resume DNA synthesis after IGF-1 treatment (Fig. 6B). 
Instead, 1C6 cells (which have down-regulated p53 and the IGF-1R is under the control 
of its own promoter) could not resume DNA synthesis (Fig. 6C). However, 1R6 cells 
(which have down-regulated p53 but an IGF-1R under the control of a CMV promoter; 
Fig. 7C) resumed DNA synthesis upon IGF-1 stimulation (Fig. 6D).  
These data confirmed that E6-mediated down-regulation of p53 in S-HML 
impaired DNA synthesis, and support the notion that the growth impairment was 
mediated through the effects of the Tag-p53 complexes on the IGF-1 signaling pathway. 
This interpretation was supported by the finding that E6 expression in HMs that do not 
contain Tag did not affect the rate of DNA synthesis in these cells (Bocchetta et al., 
2008).  
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Figure 7. IGF-1R expression in S-HML and in 1R cells. (A) Mouse preimmune IgG. 
(B) IGF-1R expression in S-HML. (C) IGF-1R expression in 1R cells. Nuclei were 
counterstained with hematoxylin. Original magnification 400 X.  
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E6-MEDIATED DOWN-REGULATION OF P53 CAUSES TRANSCRIPTIONAL REPRESSION OF 
P53-REGULATED PROMOTERS AND OF THE IGF1 PROMOTER IN S-HML 
We hypothesized that the decreased expression of p21, mdm2 and IGF-1 protein 
levels detected after E6-mediated p53 depletion in S-HML (SV40 transformed HM cells) 
could have been mediated at the transcriptional level. Treatment of S-HML with IGF-1 
caused increased expression of the IGF-1R, while a siRNA directed against IGF1 caused 
decreased IGF-1R expression in S-HML (Fig. 8). Therefore, we concluded that the study 
of the IGF-1 promoter regulation would have provided major insights into the positive 
IGF-1/IGF-1R autocrine feed-back loop in S-HML.  
                       
Fig. 8. IGF-1 regulates IGF-1R expression levels in S-HML.  (A) S-HML were 
transfected either with a control siRNA (cont.) or with a validated siRNA targeting the 
IGF1 mRNA (RNAi; 1 nmole/10
6
 cells). After transfection, cells were cultured in 
DMEM supplemented with 5% FBS. 48 hr after transfection cells were harvested and 
assayed by Western blot analysis. Results were visualized and quantitated using a 
Fujifilm LAS 3000 imaging system. Note that a reduction of about 60% of the IGF-1 
precursor was paralleled by about 3-fold reduction of the IGF-1R expression. (B) S-HML 
were cultured either in DMEM supplemented with 1% FBS (1% lane), or in DMEM 
supplemented with 1% FBS including 5 nM IGF-1 (IGF-1 lane). Note that IGF-1 
stimulation caused a 2.4-fold increase in the IGF-1R expression level in S-HML.  
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We used real time PCR to study expression of IGF1 and other genes that are 
under regulation of p53. We found that E6-mediated p53 down-regulation in S-HML 
almost abolished P21 and IGF1 mRNA expression, and caused a 50% and 80% reduction 
in the expression of the Bax (a gene also regulated by p53) and MDM2 mRNAs, 
respectively (Fig. 9A). Nuclear run-on experiments confirmed that the transcriptional 
activity of these promoters is suppressed in S-HML expressing E6 (Fig. 9B). To further 
verify that E6 induction in S-HML caused repressed transcription at the IGF1 promoter 
we performed reporter assays using a plasmid kindly provided by Dr R. Baserga (Thomas 
Jefferson University, Philadelphia, PA), in which firefly luciferase is under the control of 
the rat IGF1 promoter (Porcu et al., 1994; see Fig. 10 for the map of this plasmid).  
Inhibition of p53 by the induction of E6 in S-HML/E6 caused a 70% reduction of 
firefly luciferase activity as compared to controls (Fig. 9C). This suggests that the 
presence of p53 along with Tag is required to transactivate IGF1 expression. We 
hypothesized that either Tag or p53 (or both) directly binds to the IGF1 promoter and 
regulates its transcription. We first tested this hypothesis using the rat IGF1 promoter, 
since it was previously characterized (Porcu et al., 1994) and the results supported our 
hypothesis (Bocchetta et al., 2008). The results in the rat model suggested that Tag and 
cellular p53 can directly or indirectly associate with the IGF1 promoter in S-HML. 
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Figure 9. E6 induction in S-HML causes transcriptional repression at p53-regulated 
promoters. Tag and p53 bind to the rat IGF-1 promoter in vitro. (A) Steady-state 
levels of the Bax, p21, mdm2 and IGF-1 mRNA in S-HML transfected with a control 
plasmid (C columns) and with a plasmid expressing recombinant E6 (E6 columns). The 
measurements were taken 48 hr after transfection. The histogram represents the average 
of 4 independent experiments, each measurement was taken in triplicate over a curve of 6 
dilutions of cDNAs. GAPDH mRNA was used as the internal control for each sample. 
Setting the control plasmid-transfected S-HML at 100%, the E6 transfected S-HML 
displayed the following averages: Bax, 20.59 ± 14.71%; p21, 0.32 ± 0.04%; mdm2, 53.75 
± 11.25%; IGF-1, 0.02 ± 0.01%. (B) Left: representative nuclear run-on experiment 
performed on nuclei of S-HML transfected either with the control plasmid or the E6-
expressing plasmid. The experiments were conducted 48 hr after transfection. 
Radioactivity associated with each band was measured with a phosphoimager. Right: 
average of four independent experiments. Setting the controls at 100%, the E6 transfected 
S-HML displayed the following averages: p21, 19.84 ± 12.70%; IGF-1, 23.80 ± 17.46%; 
Bax, 26.98 ± 20.63%; 18S, 92.06 ± 12.70%. Error bars represent standard deviation. (C) 
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Reporter assay conducted on S-HML/E6 and control cells in the presence and the 
absence of doxycycline. Firefly luciferase was under the control of the rat IGF1 promoter 
(pSmaBgl-LUC0). Cells were transfected, then cultured in the presence or absence of 
antibiotic. 48 hr after culturing, 10 µg of total cell lysates were assayed for the luciferase 
activity. The values were measured as firefly luciferase units/renilla luciferase light units. 
The histogram is the average of 12 independent experiments. The results were as follows: 
control cells cultured in the absence of doxycycline: 97.89 ± 30.53; control cells cultured 
in the presence of 2 µg/ml doxycycline: 95.79 ± 34.73; S-HML/E6 cultured in the 
absence of doxycycline: 83.16 ± 28.42; S-HML/E6 cultured in the presence of 2 µg/ml 
doxycycline: 26.32 ± 16.21. Asterisk: P > 0.01. Courtesy of Maurizio Bocchetta. 
 
 
 
 
 
 
Fig. 10. Map of pSmaBgl-LUC plasmid. Plasmid map provided by Dr Renato Baserga 
(see also ref. Porcu et al., 1994). 
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TAG AND CELLULAR P53 ASSOCIATE WITH THE IGF1 PROMOTER WITHIN A IN VIVO 
To test whether Tag and cellular p53 were associated with the IGF1 promoter in 
S-HML we resorted to chromatin immunoprecipitation (ChIP) assays. We aligned the 
sequence of the rat promoter with the genomic sequence of the human IGF1 region. The 
fragment in the human IGF-1 promoter that showed the highest homology with the rat 
promoter (72% nucleotide identity) was the one spanning positions -1952 to -322 of the 
human IGF1 promoter (+1 is the IGF1 initiation codon). This promoter region was 
analyzed by ChIP assay dividing the 1630 bp DNA promoter region in 7 partially 
overlapping amplicons (Fig. 11A).  
 
Figure 11. Tag and p53 associate with the IGF1 promoter. (A) Schematic of the 
region of the IGF1 promoter that was assayed by ChIP. Tag and p53 associate only with 
region A and B. (B) ChIP assay performed on untransfected S-HML. Abbreviations: H20, 
reaction performed in the absence of any template; con, immunoprecipitation (IP) 
performed using a pre-immune serum as the primary antibody; Tag, IP performed with an 
anti-Tag as the primary antibody; p53, IP performed with an anti-p53 as the primary 
antibody; p300, IP performed with an anti-p300 as the primary antibody; input, 10% of 
the total input DNA. (C) ChIP assay performed on transfected S-HML. Abbreviations: c, 
S-HML transfected with a control plasmid; E6, S-HML transfected with the E6 
expressing plasmid; con, IP performed using a pre-immune serum as the primary 
antibody; input, 10% of the total input DNA. (D) ChIP assays performed using anti pRb 
and p300 as the primary antibodies. Abbreviations are the same as in Panel C. The 
experiments shown here were repeated three times.  
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As a negative control, we used a 266 bp region on chromosome 12q12, a region 
distant from any known gene. We compared non-transfected S-HML to p53-depleted S-
HML via E6 transfection. Cells were cross-linked, then cell lysates were mechanically 
sheared and immunoprecipitated with antibodies specific for either Tag (Fig. 11B, lanes 
3) or p53 (Fig. 11B, lanes 4). The crosslinking in immunoprecipitated materials was 
reversed and PCR-amplified with primers that yielded the amplicons outlined in Fig. 
11A. In non-transfected S-HML (cells with an active IGF1 promoter) Tag was associated 
with the “B” region, and p53 was associated with both the “A” and “B” regions (Fig. 
11B). Instead, in p53-depleted S-HML, p53 was associated only with the “B” region (Fig. 
11C, lanes 7 and 8), and Tag was associated prevalently with the “A” region (Fig. 11C, 
upper panel, compare lanes 5 and 6), although the signal corresponding to the “B” region 
persisted (Fig. 11C, lanes 5 and 6, bottom panel). This indicated that upon E6-mediated 
p53 down-regulation the Tag-p53 complex on the IGF1 promoter underwent a 
conformational change, with Tag moving upstream (i.e. to the A region) from the IGF1 
starting codon and p53 losing occupancy of the same region. To further investigate the 
Tag-p53 complex on the IGF1 promoter, we tested the “A” through “G” region of the 
IGF1 promoter by ChIP for two major binding partners of Tag: pRb and p300 (reviewed 
in Ali and DeCaprio, 2001). When we immunoprecipitated S-HML extracts using a pRb-
specific antibody we PCR-amplified region “B” (Fig. 11D, lane 3). When we 
immunoprecipitated using a p300-specific antibody we amplified both “A” and “B” 
regions (Fig. 11B, lane 8). No other region of the portion of the IGF1 promoter was 
amplified. These data indicated that within the 538 bp encompassing the “A” and “B” 
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regions of the IGF1 promoter there is a multi-protein complex that includes Tag, p53, 
pRb, and p300. When we decreased p53 expression through E6 induction we were still 
able to amplify region “B” by immunoprecipitating with the pRb-specific antibody (Fig. 
11D, lane 7), however immunoprecipitations conducted with the p300 antibody failed to 
yield both the “A” (not shown) and “B” amplicons (Fig. 11D, lane 8). This indicated that 
upon p53 depletion, the multi-protein complex at regions -1952 to -1414 of the IGF1 
promoter underwent modifications that included structural rearrangements of individual 
complex partners and exit of p300, a transcriptional co-activator (Ogryzko et al., 1996). 
The result of these modifications was paralleled by transcriptional inhibition at the IGF1 
promoter. We detected no quantitative differences in the amount of pRb bound to the “B” 
amplicon before and after E6-mediated p53 depletion in S-HML using quantitative PCR 
(Bocchetta et al., 2008). No E6 association with the IGF1 promoter was detected. 
Furthermore, no association of either Tag or p53 was detected on the IGF1R promoter 
using ChIP analysis (not shown). 
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DISCUSSION 
Here we present evidence that Tag/p53 complexes bind to the IGF1 promoter, 
stimulating IGF1 expression and the IGF-1 signaling pathway, an effect that leads to cell 
growth. Specifically, we found that the Tag/p53 complexes interact with the IGF1 
promoter as part of a complex that consists of several partners, including pRb and p300. 
When we depleted p53 we observed a loss of p300 on the IGF1 promoter. Our results 
provide an explanation for a number of studies that had found that the presence of wild-
type p53 was required to stimulate transcription in polyomaviruses-mediated malignant 
cell transformation (Long et al., 1995; Sheppard et al., 1999; Technau et al., 2001; 
Michalovitz et al., 1986; Deppert et al., 1989; Herzig et al., 1999). 
One of the current views about p53 is that its transcriptional and biological 
activities are impaired by its binding to the Tags of DNA tumor viruses. A similar view 
in the DNA tumor virus field assumes that the oncogenes of these viruses bind to and 
“inactivate” cellular p53, a process that is required for viral replication and also for virus-
mediated cellular transformation. Here we present evidence that this vision is incorrect, 
because downregulation of p53 caused decreased expression of p53 regulated genes. This 
supports the idea that in SV40-transformed HM p53 retains at least some transcriptional 
regulation activity. More importantly, Tag/p53 complexes acquire new transcriptional 
and biological activity. These findings support recent studies, showing that Tag requires 
p53 to interact with p300, and RNAi-mediated p53 depletion disrupted Tag-p300 
interactions (Borger and DeCaprio, 2006). Therefore, we propose the following model 
(Fig. 12).  
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Fig. 12. Model of Tag/p53 regulation of the IGF1 promoter. Top: In S-HML cells, 
with active transcription at the IGF1 promoter, a protein complex (which includes Tag, 
p53, pRB, p300 and very likely other members) occupies a region spanning positions -
1952 to -1414 of the IGF-1 promoter. Bottom: Upon p53 depletion this protein complex 
undergoes a number of rearrangements that include spatial redistribution of members of 
this complex (e.g., Tag translocates upstream in the promoter), loss of protein 
components (e.g., p300 and a fraction of p53). This rearranged complex interferes with 
transcription of the IGF1 gene.  
 
In normal S-HML a multiprotein complex that includes Tag, p53, pRb and p300 
occupies positions -1952 to -1414 (+1 is transcription start site) of the IGF1 promoter. 
Upon p53 depletion (obtained using different techniques) this complex undergoes 
structural rearrangements, probably as a result of the exit of some critical components 
(such as p300) that ultimately regulate the transcription of the IGF1 gene.  
The biological effects observed upon SV40 infection are species specific (Gazdar 
et al., 2002) because rodent cells are non-permissive to SV40 replication, whereas human 
cells are. Therefore, animal models could not be used to test, in vivo, the possible 
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oncogenic effects of the findings reported here. Nonetheless, one study in mice 
reported higher SV40-mediated oncogenicity (Tag transgenic mice where Tag was under 
a control of insulin promoter in the % pancreatic cells) in wild type mice compared to p53 
null mice (Herzig et al., 1999). 
In our experimental model we used mesothelial cells and SV40. Specifically, we 
used different primary HM obtained from separate donors with non-malignant pleural 
effusions (Bocchetta et al., 2000). We used HM because these cells allow SV40 
replication and are rarely lysed by the virus, thus HM are ideal to study the biological 
interactions among Tag and p53 (Bocchetta et al., 2000). HM are also frequently 
transformed by SV40 (Bocchetta et al., 2000; Gazdar et al., 2002), an effect that allowed 
us to compare the Tag/p53 biological activities in both primary and malignant human 
cells. Given that similar effects were observed in SV40-transformed primary human 
astrocytes (brain tumor is the second most common tumor type related to SV40), the 
results presented are potentially of general relevance (Bocchetta et al., 2008). It should be 
noted that p53 depletion caused decreased IGF1R expression in both S-HML and SV40-
transformed human astrocytes. Although no direct association of p53 or Tag was detected 
on the IGF-1R promoter, Tag/p53 complexes may regulate IGF1R expression indirectly 
(Valentinis et al., 1994). Alternatively, the expression of IGF1R may be mainly under the 
control of a positive feed-back loop regulated by autocrine IGF-1.  
In summary, our data provide evidence that SV40 directly manipulates the IGF-
1/IGF-1R signaling pathways to promote HM malignant transformation. This situation 
implicates the dysregulation of IGF-1 signaling as a putative early pathogenic event in 
!    
 
52!
the onset of MM. We propose that exacerbated IGF-1R signaling (and downstream 
Akt-1 activation) may allow fiber-damaged cells’ survival, an event that would favor 
further genetic damage that may ultimately lead to MM progression. 
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CHAPTER 4 
THE ROLE OF NOTCH SIGNALING IN MALIGNANT 
MESOTHELIOMA 
 
ABSTRACT 
Malignant mesothelioma (MM) is a cancer of the lining of the lungs, heart, and 
intestine and is known to respond poorly to chemotherapy. Here we show that malignant 
mesothelial cells have elevated Notch-1 signaling as compared to normal human 
mesothelial cells (HM). We studied the role of Notch in MM under normoxic and 
hypoxic conditions, the later condition best recapitulating the MM microenvironment. 
Genetic and chemical modulation of the Notch pathway indicated that MM cells are 
dependent on Notch signaling. More specifically, this signaling was Notch-1 dependent 
as the result of its negative transcriptional regulation on phosphatase and tensin homolog 
(PTEN), which led to activation of the pro-survival Akt-1 signaling pathway. 
On the contrary, Notch-2 expression is lost in MM. This differential expression of 
the two Notch isoforms benefits cancer cell survival as re-expression of Notch-2 was 
toxic to MM cells. The mechanism of Notch-2 toxicity to MM cells countered that of 
Notch-1 as it was the result of positive transcriptional regulation of PTEN and inhibition 
of the Akt-1 signaling pathway. These results provide new insight into the role of Notch
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in MM and suggest that Notch pathway inhibitors may be useful in the treatment of 
this deadly disease.  
 
INTRODUCTION 
MM is among tumors with the shortest median survival after diagnosis, with little 
benefit provided by current chemotherapies (Carbone et al., 2002). MM has been linked 
to environmental fibers exposure (asbestos and erionite; Gazdar et al., 2002), SV40 
infection (Gazdar et al., 2002, Kroczynska et al., 2006), however genetic predisposition 
may also play a role in MM (Carbone et al., 2007, Dogan et al., 2006). Mesothelioma is 
generally treated with surgical resection followed by adjuvant chemotherapy (Burgin et 
al., 2009). Non-resectable MM cases are treated with a combination of pemetrexed (a 
folate antimetabolite) and cisplatin (Burgin et al., 2009). However, the median survival 
after diagnosis is still a dismal 12.7 months. It is therefore essential to obtain a better 
understanding of the molecular mechanisms that underlie MM and to identify novel 
therapeutic strategies for the treatment of this disease.  
Our previous work in adenocarcinoma of the lung (ACL) reveals that when 
studying molecular pathways in solid tumors, one needs to take into account the 
oxygenation status of the tumor tissue (Chen et al., 2007). In this regard, it should be 
underscored that MM is a severely hypoxic malignancy (Klabatsa et al., 2006). Hypoxic 
microenvironment seems to profoundly affect signaling through Notch receptors 
(especially Notch-1). Hypoxia inducible factor-1& (HIF-1&) has been shown to stabilize 
Notch-1
IC
 and to greatly increase Notch-1/CBF-1-mediated transcriptional activity in 
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myogenic and neuronal stem cells (Gustafsson et al., 2005). We have confirmed these 
effects in ACL cells, where we showed that in hypoxic conditions Notch-1 provides 
essential survival signals to ACL (Chen et al., 2007).  
Notch signaling has been increasingly linked to cancer, although the biological 
effects of Notch activity appear to be tissue-specific. Activated Notch signaling was 
confirmed in T-cell acute lymphoblastic leukemia (T-ALL; Weng et al., 2004), breast 
(Reedijk et al., 2005) and prostate cancer (Santagata et al., 2004). Notch-1 is a tumor 
suppressor in mouse and human skin (Nicolas et al., 2003; Thelu et al., 2002). Ectopic 
expression of Notch-1
IC
 led to growth arrest of SCLC (Sriuranpong et al., 2001). In 
certain tumor types the role played by specific Notch receptors is still debated.  
In a previous study, we showed that Notch-1 activation was required during the 
process of SV40 mediated transformation of primary human mesothelial cells (HM) 
(Bocchetta et al., 2003). Inhibition of Notch-1 activation led to growth arrest of SV40-
transformed HM (Bocchetta et al., 2003). In this chapter we analyze the role of Notch 
signaling in MM in general (e.g., irrespective of SV40). Given that the effects of Notch 
signaling are dose-, time- and context-dependent (Lewis, 1998), we plan to study Notch 
signaling taking all those variables into account. Specifically, tumor microenvironment 
appears to play a role in mediating crucial molecular events, especially hypoxia and 
Notch signaling (Gustafsson et al., 2005; Chen et al., 2007). Since MM is among the 
most hypoxic solid tumors, we analyze the role of Notch in MM in hypoxic conditions.   
Based on the results presented in Chapter 3, and the evidence that insulin-like 
growth factor-1 (IGF-1) signaling is important for HM transformation and the 
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maintenance of the transformed phenotype, in this section we want to determine 
whether Notch interacts with the IGF-1/Akt-1 pro-survival pathway. Our findings 
indicate that Notch-1 and Notch-2 play opposite roles in MM cell survival. Expression of 
Notch-1 leads to the down-regulation of PTEN, Akt-1 activation, increased DNA 
synthesis and MM cells survival, while Notch-2 induction leads to PTEN activation, Akt-
1 dephosporylation and MM cell death. 
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MATERIALS AND METHODS 
 
CELL CULTURE, HYPOXIA, GAMMA-SECRETASE INHIBITOR AND RNA STUDIES 
Primary human mesothelial cell cultures (HM) were obtained and characterized 
from ascites fluids obtained from non-cancerous patients as previously described 
(Bocchetta et al., 2000). HM were grown in DMEM supplemented with 10% FBS. 
Mesothelioma cell lines (ME) were obtained and characterized from primary tumors as 
previously described (Pass et al., 1995). ME were grown in DMEM supplemented with 
10% FBS. All cells were fingerprinted using the GenePrint fluorescent STR system 
(Promega). Cells grown in hypoxia were maintained in chambers (Stem Cell 
Technologies) filled with certified 1% O2, 5% CO2 and 94% N2 (Airgas North Central) at 
37 °C. Oxygen concentration was measured with MiniOX1 oxygen meters (Mine Safety 
Appliances Company). 
The gamma secretase inhibitor (GSI) MRK-003 was dissolved in DMSO to make 
40 mM stock solutions.  
Laser capture microdissection was performed on 8 µm-thick frozen MM and 
normal lung specimens using a Pixcell II Laser capture Microdissection System (Arcturus 
Engineering Inc.). Normal human pleura (HP) was captured from normal lung biopsies 
after identifying mesothelial cells using the Histogene® LCM Immunofluorescence 
Staining Kit (Molecular Devices) with some modifications. Briefly, we used a 
biotinylated primary antibody specific for mesothelin, following the manufacturer’s 
protocol. Cy3-streptavidin was replaced with HRP-conjugated streptavidin, and color was 
!    
 
58!
developed in 3’ using the DAB substrate (Vector). Samples were rapidly de-hydrated, 
and processed for laser capture microdissection. MM specimens were stained using the 
HistoGene
TM
 LCM frozen section staining kit (Arcturus) and microdissected as described 
above. We collected ~500 cells for each sample. RNA was extracted using the 
PicoPure
TM
 RNA isolation kit (Arcturus) and amplified using the RiboAmp
TM
 RNA 
amplification kit (Arcturus; 1/4 of the original total RNA preparation was used directly 
for 18S rRNA normalization). Total RNA was purified from cultured cells using the 
RNeasy Mini kit (Qiagen). Reverse transcription and Real Time PCR analysis were 
performed as described (Chen et al., 2007). Briefly, quantitative real-time PCR was 
performed with SYBR Green PCR Master Mix (Applied Biosystems) in an ABI 7300 
thermal cycler (Applied Biosystems). For each sample, a serial dilution of cDNA 
template was measured in triplicate. Non-RT reactions served as controls. All 
measurements were normalized for 18S rRNA. Comparison between groups were 
analyzed by Student’s t-test, with alpha < 0.05. 
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PLASMIDS AND LENTIVIRAL SYSTEMS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4. List of all oligonucleotides used in Chapter 4 
 
Sequences of oligonucleotides used in this chapter are provided in Table 4. A list 
of antibodies used in this chapter is reported in Table 5. Notch-1
IC
 and Notch-2
IC
 cloned 
into pcDNA3.0 (Invitrogen) have been previously described (Chen et al., 2007). The 
same inserts were subcloned into pLenti4/TO/V5-DEST to generate the Notch-1
IC
-DEST 
 
 
 
Primer Sequence 
Notch-1 F 5’-TGTTGTGTGTCATGCCAGTG-3’ 
Notch-1 R 5’-AACATCTTGGGACGCATCTG-3’ 
Notch-2 F 5’-GCCTGGCAGTGTTACCTCAT-3’ 
Notch-2R 5’-GTCCCTGAGCAACCATCTGT-3’ 
HEY-1 F 5’-TCCTGCCTCCTTCTCTTTGA-3’ 
HEY-1 R 5’-CCAGTTCAGTGGAGGTCGTT-3’ 
HES-5 F 5’-GCCCGGGGTTCTATGATATT-3’ 
HES-5 R 5’-GAGTTCGGCCTTCACAAAAG-3’ 
PTEN F 5’-ACCAGGACCAGAGGAAACCT-3’ 
PTEN R 5’-GCTAGCCTCTGGATTTGACG-3’ 
18S F 5’-TGATTAAGTCCCTGCCCTTTGT-3’ 
18S R 5’-TCAAGTTCGACCGTCTTCTCAG-3’ 
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and Notch-2
IC
-DEST to obtain doxycyline-inducible expression of either Notch-1
IC
 or 
Notch-2
IC
 in lentiviral vectors (the backbone system was the ViraPower T-Rex Lentiviral 
System; Invitrogen). 
 
ANTIBODIES 
Target Type Company Cat. number 
Notch-1 (C-20) Rabbit polyclonal Santa Cruz Biotech. SC-6014R 
Active Notch-1 Rabbit Cells Signaling 2421s 
Notch-2 Rabbit polyclonal Abcam ab8927 
Notch-3 (M-134) Rabbit polyclonal Santa Cruz Biotech. SC-5593 
Notch-4 (L-16) Goat polyclonal Santa Cruz Biotech. SC5594 
Jagged-1 Goat polyclonal Santa Cruz Biotech. SC-6011 
Delta-1,4 Goat polyclonal Santa Cruz Biotech. SC-8155 
Hes-1 Mouse monoclonal BD Transduction Lab. 611596 
Hes-5 Goat polyclonal Santa Cruz Biotech. SC-13859 
Hrt-1 (H-120) Rabbit polyclonal Santa Cruz Biotech. SC-28746 
Akt Goat polyclonal Santa Cruz Biotech. SC-1618 
p-Akt Rabbit monoclonal Cells Signaling 4058 S 
p-mTOR Rabbit polyclonal Cells Signaling 3061S 
p-Pdk-1 Rabbit polyclonal Cells Signaling 2971 S 
Pdk-1 Rabbit polyclonal Cells Signaling 3062 
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PTEN Rabbit polyclonal Cells Signaling 9552 
p21 Mouse monoclonal Santa Cruz Biotech. SC-817 
GAPDH Mouse monoclonal Chemicon MAB374 
p-Jnk Rabbit polyclonal Cell Signaling 2676 
Bax Rabbit polyclonal Santa Cruz Biotech. SC-493 
Bcl-2 Rabbit polyclonal Santa Cruz Biotech. SC-8351 
IL-7 Rabbit polyclonal Santa Cruz Biotech. SC-7921 
Mesothelin Mouse monoclonal Santa Cruz Biotech. SC-33672 
Pancytokeratin Mouse monoclonal Zymed 18-0132 
Carcinoembryonic  
Antigen 
Mouse monoclonal Zymed 18-0057 
Calretinin Mouse monoclonal Zymed 18-0291 
 
     Table 5.  List of all antibodies used in Chapter 4 
 
A short hairpin targeting Notch-1 (shNotch-1) was obtained by annealing 
complementary DNA oligonuclotides (Chen et al., 2007); the resulting double-stranded 
DNA was ultimately cloned in pLenti4/TO/V5-DEST to obtain a tetracycline-inducible 
lentiviral system conditionally expressing shNotch-1. 
We generated 4 tetracycline-inducible ME stably expressing the genes of interest 
under the control of the TR (tetracycline regulator) as follows. First, cells were 
transduced with the TR lentivirus and selected with blastycidin (3 µg/ml); then they were 
transduced either with Notch-1
IC
, Notch-2
IC
, or shNotch-1, and selected with zeocin (200 
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µg/ml) according to the manufacturer’s instructions. Cells transduced with the empty 
pLenti4/TO/V5-DEST lentiviral vectors (abbreviated pDest in most Figures) were used 
as the controls. In different set of experiments, we artificially downregulated Notch-1 and 
Notch-2 expression using commercially available siRNAs (Santa Cruz Biotechnologies). 
The non-specific siRNA (negative control) was commercially available (Santa Cruz 
Biotechnologies). Constitutively active Akt-1 (N-terminal myristoylatable Akt-1) cloned 
into the pUSEamp(+) expression plasmid (abbreviated as “pUSE” in Figures) was 
purchased from Upstate (Millipore). Transient transfections were performed using an 
electroporator (Gene Pulser II, Biorad) under the following parameters: 300kV and 975 
µF capacity; 1 µg of plasmid DNA/ 106 cells. Efficiency of transfection was >95%. 
 
FLOW CYTOMETRY AND PROTEIN STUDIES 
Cells handled in different experimental settings were analyzed by flow cytometry 
upon Annexin V-PE (BD Pharmingen)/ 7-aminoactinomycin D (7-AAD; Sigma) staining, 
PI staining (Sigma) or BrdU incorporation (FITC BrdU Flow kit, BD Pharmingen). 
FACS analysis was performed on a BD FACSCanto instrument (Becton Dickinson) 
measuring 30,000 events for each sample. 
Western blot analyses were performed as described (Chen et al., 2007).  
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CHROMATIN IMMUNOPRECIPITATION ASSAYS 
1 x 10
7
 cells were cultured in hypoxia for 48 hours. Cells were then washed and 
cross-linked for 10 min at a room temperature using 1% formaldehyde in PBS. The 
reaction
 
was stopped, by adding 0.25
 
M glycine in PBS. The cells were harvested and the 
DNA was sheared by sonication in lysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 
1% NP-40) supplemented with 1% SDS, using a Branson SONIFIER 250 (Wolf 
Laboratories Lmd, UK) to
 
generate DNA fragments $600 bp. Cell lysates were diluted 
ten times with lysis buffer to reduce the SDS final concentration to 0.1%. Lysates were 
precleared with protein A/G agarose beads (Pierce, Rockford, IL) for 4 hr
 
at 4°C, and 
were then incubated overnight at 4°C with the respective primary
 
antibodies. Immune
 
complexes were collected on Protein A/G agarose beads overnight at 4°C. Samples were 
dialyzed twice against dialysis buffer (2 mM EDTA pH 8.0, 50 mM Tris-HCl pH 8.0). 
Following 4 washes in 1 ml wash buffer (100 mM Tris-HCl pH 8.0, 500 mM LiCl, 1% 
NP-40); immune complexes were eluted
 
from the beads by vigorously shaking twice for 
15 minutes in 150 µl of 50mM NaHCO3, 1% SDS. Cross-linking
 
was reversed by 
incubation in 0.15 M NaCl overnight at 65°C.
 
Each sample’s DNA was ethanol 
precipitated and purified using QIAprep spin miniprep kit (Qiagen).
 
DNA was 
resuspended in 100 µl of TE buffer. Finally, each sample was PCR amplified using 
appropriate oligonucleotides as primers (Table 7), and the results were visualized on 2% 
agarose gels.  
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RESULTS 
NOTCH-1 EXPRESSION LEVELS ARE ELEVATED IN BOTH MESOTHELIOMA CELL LINES AND 
SPECIMENS AS COMPARED TO THEIR NORMAL COUNTERPARTS 
First, we measured the expression levels of Notch receptors, ligands and 
downstream Notch targets in 8 ME compared to 3 HM. Western blot analyses showed 
that all ME had increased Notch-1, Jagged-1 (and, to a lesser extent, Notch-3) expression 
levels as compared to HM (Fig. 13A). According to the pattern of expression of Notch 
receptors and ligands, ME displayed increased expression of the Notch downstream 
targets HES-1, HEY-1 and HES-5 as compared to HM (Fig. 13B, Top). Treatment of ME 
with the proteasome inhibitor MG132 led to an increase of the Notch-1
IC
 expression, 
suggesting activation followed by degradation (Gupta-Rossi et al., 2001) in these cells as 
compared to HM (Fig. 13B, bottom). ME appeared to have significantly decreased (or 
abolished) Notch-2 expression levels as compared to HM (Fig. 13A). Notably, we 
detected Notch-2 immunoreactivity only in one frozen MM out of 25 specimens 
analyzed, while the same samples tested positive for Notch-1
IC
 staining, indicating that in 
MM samples Notch-2 protein is poorly or not expressed (Graziani et al., 2008). These 
results were confirmed at the mRNA level. ME and MM cells had substantially higher 
levels of Notch1 mRNA as compared to HP, while the opposite was measured with 
Notch2 mRNA (Fig. 13C). Based on HEY1 and HES5 (Fig. 13D) results, Notch signaling 
is elevated (> 10-fold) in ME and MM compared to HP, and Notch-1 appears to play a 
predominant role in this activation. The mRNA expression pattern in ME mimics what 
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was observed in MM, suggesting that our in vitro cell line is a good model for studying 
MM. 
 
 
Figure 13. Expression of Notch signaling components in primary human mesothelial 
cell cultures (HM), mesothelioma cell lines (ME), microdissected lung pleura (HP) 
and microdissected mesothelioma cells (MM). (A) Western blot analysis performed on 
3 independent HM and 8 ME of the indicated gene products. Note upregulated Notch-1 
receptor and Jagged-1 ligand in ME compared to HM. Notch-3 also appears to be 
upregulated in ME compared to HM. (B) Top; Western blot analysis of the Notch 
downstream target HES-1, HEY-1 and HES-5 in HM and ME. Bottom; Western blot 
analysis of Notch-1
IC
 in HM2b and ME17 in the presence (+) and in the absence (-) of the 
proteasome inhibitor MG132 (10 µM final concentration). Cell extracts were prepared 24 
hr after MG132 addition. (C) Real time PCR analysis performed on RNA extracted from 
HM (a colums), HP (b columns), ME (c colums) and MM (d colums). Expression of the 
indicated mRNAs was normalized for 18S rRNA expression of each sample. Columns in 
the histograms represent the averages of results obtained in 4 independent experiments (4 
microdissected, frozen lungs, 4 microdissected, frozen MM, 4 HM and 4 ME). Error bars 
represent standard deviation. T test P values: * (ME vs. HM), > 0.0001; ** (MM vs. HP), 
0.0004; # (ME vs. HM), 0.0001; ## (MM vs. HM), > 0.0001. (D) Real Time PCR 
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analysis performed on RNA extracted from HM, HP, ME and MM. Expression of the 
indicated mRNAs was performed and normalized as described in C. T test P values: ‘ 
(ME vs. HM), > 0.0001; “ (MM vs. HP), 0.0012; ^ (ME vs. HM); > 0.0001; ^^ (MM vs. 
HP), 0.0004. Courtesy of Irene Graziani. 
 
 
INHIBITION OF NOTCH-1 CAUSES ME CELL DEATH, BOTH IN NORMOXIA AND HYPOXIA. 
To understand the role of Notch-1 expression in ME and MM, we artificially 
inhibited Notch-1 in ME, and analyzed the biological effects of such manipulation. We 
employed a specific shRNA targeting Notch1 (shNotch-1) expressed using tetracycline-
inducible lentiviral system activated by doxycycline treatment. Abrogation of Notch-1 
signaling using this approach caused complete ME cell death both in normoxia (Fig. 
14A) and under hypoxia (not shown). Similar effect on cell viability was observed after 
GSI treatment, the effects however appeared to be greater under hypoxia. This is 
reflected by a 6.72 ± 0.58 fold increase of Annexin V/ 7’AAD staining of various ME 
treated with GSI (5µM) cultured under hypoxia (Fig. 14B) compared to a 3.22 ± 0.49 (P 
value > 0.01) fold increase in cell death observed in normoxia. Both artificial down-
regulation of Notch-1 and GSI treatment appeared to depress the Akt-1 pathway activity. 
Artificial down-regulation of Notch-1 using a small interfering RNA (siRNA) targeting 
Notch1 under hypoxia caused decreased phosphorylation of PDK-1, Akt-1 and the 
downstream effector mTOR protein expression (Fig. 14C). Downregulation of Notch-1 
through siRNA caused increased expression of Notch-2 and decreased expression of 
Notch-3 and -4. This indicated that Notch-1 may negatively regulate Notch-2, while 
positively regulating Notch-3 and -4 expression in ME.  
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Figure 14. Down-regulation of Notch-1 in ME leads to cell death both in normoxia 
and hypoxia. (A) representative down-regulation of Notch-1 expression obtained using a 
lentiviral vector that expresses a short hairpin targeting the Notch-1 mRNA (shNotch-1) 
upon stimulation with doxycycline. Top; Western blot analysis of Notch-1 in shNotch-1 
and control cells (pDest) 24 and 48 hr after doxycycline addition. Middle; Cristal violet 
staining of either shNotch-1 and control cell cultures 5 days after doxycycline treatment. 
Bottom; quantification of 4 independent experiments (10,000 alive cells were plated in 
each 100 mm dish before doxycycline stimulation). Error bars represent standard 
deviation. P value: * >0.0001. These experiments were performed in a standard incubator 
(21% oxygen, 5% CO2). (B) representative Annexin V/7 Aminoactinomycin D (7AAD) 
staining of a ME treated either with DMSO (Top) or with 5 µM GSI in DMSO (Bottom). 
All cells were cultured under hypoxia. (C) Western blot analysis of the indicated gene 
products of ME14 treated either with a control siRNA (Control) or with a siRNA 
targeting the Notch-1 mRNA (siNotch-1). The analysis was performed 48 hr after 
transfection. All cells were cultured in hypoxia. (D) Western blot analysis of the 
indicated gene products of ME16 treated with the specified concentrations of the GSI. 
Analysis was performed 24 hr after GSI treatment. All cells were cultured in hypoxia. 
Experiments were replicated three times. 
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Treatment of ME cells with GSI caused a dose-dependent accumulation of the 
transmembrane (uncleaved) form of Notch-1, accompanied by a progressive decrease of 
Notch-1
IC
 and HEY-1 expression (all effects indicative of an effective Notch-1 inhibition; 
Fig. 14D). Alongside Notch-1 inhibition Akt-1 was progressively losing phosphorylation 
on Ser-473, which suggested decreasing activity of this kinase (Fig. 14D). Accumulation 
of transmembrane (uncleaved) form of the receptor after GSI treatment was most 
pronounced for Notch-1 isoform as compared to the other Notch paralogs (Fig. 14D), 
indicating that Notch-1 was the major isoform of the receptor stabilized by the GSI in 
ME.  
Since we found that inhibition of Notch-1 using different strategies causes 
decreased signaling through Akt-1 pathway, we wanted to determine whether expression 
of active form of Akt-1, can result in a decrease of GSI induced cell death. ME 
transfection with constitutively active form of Akt-1 (myrAkt) substantially rescued GSI-
induced cell death by ~50% (Fig. 15A). This rescue was paralleled by the reactivation of 
Akt-1 signaling as indicated by increased p-mTOR expression in myrAkt-transfected 
cells (Fig. 15B). Similar results were found after downregulation of Notch-1 in ME cells 
using siRNA. ME cells transfected with siRNA targeting the Notch1 mRNA displayed 
decreased Notch-1 protein expression (Fig. 15C, lanes b and d) and reduced viability 
under hypoxia (Fig. 15D, column b). When co-transfected with myr-Akt, ME cells still 
have decreased Notch-1 expression levels, but their viability was restored (Fig. 15D, 
column d).  
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Figure 15. Active Akt-1 rescues apoptosis caused by Notch-1 inhibition (A) Annexin 
V/7 aminoacinomycin D (7AAD) staining of the cells treated as in B. Each subpanel has 
been assigned with a letter, which correspond to each lane shown in B. (B) Western blot 
analysis of the indicated gene products performed on ME15 cells transfected with a 
control plasmid (pUSE) or with a plasmid expressing myristoylated (active) Akt-1 
(myrAkt). Transfected cells were either treated with DMSO or with 2 µM GSI in DMSO. 
24 hr after treatment cells were assayed for apoptosis A. (C) ME14 transfected with 
pUSE (control, lanes a and b) or with myrAkt (lanes c and d) and cotransfected with 
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either a control siRNA (C, lanes a and c) or with a siRNA targeting the Notch1 mRNA 
(siN1, lanes b and d). Western blot analysis of the indicated proteins. (D) Crystal Violet 
staining of colonies obtained 5 days after cotransfecting ME11, 12, 13 and 14 with the 
nucleic acids specified in C. After transfection, 10,000 live cells (as for trypan blue 
staining) for each sample were seeded in T75 flasks. Colonies were stained and counted 5 
days after seeding. The bars are the average of 4 independent experiments (one for each 
cell line). Error bars represent standard deviation. Bars: a, pUSE + control siRNA 
cotransfection; b, pUSE + siNotch-1 cotransfection; c, myrAkt + control siRNA 
cotransfection; d, myrAkt + siNotch-1 cotransfection. P values: * (a vs. b) > 0.0001; ** 
(d vs. b) 0.003. ME11, 12, 13 and 14 cell lines were derived from different patients. (E) 
Two representative microscopical fields of the samples reported in panel D, column a. 
Original magnification 40X. (F) Western blot analysis of ME cells transfected with either 
a control siRNA or with a siRNA to Notch1.  
 
These observations further confirmed that Notch-1 provides survival signals to 
ME under hypoxia mainly through the Akt-1 signaling pathway, and that a depressed 
level of Akt-1 activation contributes to ME cell death upon Notch-1 down-regulation, 
obtained either through genetic manipulation or chemical inhibition. 
 
NOTCH-2 SIGNALING CONTRASTS THE NOTCH-1 PRO-SURVIVAL SIGNALS IN ME CELLS.  
In contrast to the elevated levels of Notch-1 in ME and MM, we observed reduced 
(or suppressed) Notch-2 expression in both ME and MM samples as compared to their 
normal counterparts (Fig. 13). Our results confirm that Notch-2 signaling induced 
programmed cell death in ME, and this effect was largely mediated through modulation 
of Akt-1 activity, since Notch-2
IC
 expression depressed Akt-1 signaling, and the 
introduction of a constitutively active Akt-1 mutant reversed the pro-apoptotic effects 
induced by Notch-2
IC
 under hypoxia (Graziani et al., 2008).  
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NOTCH-1 AND NOTCH-2 HAVE OPPOSITE EFFECTS ON THE AKT-1 SIGNALING PATHWAY 
BECAUSE OF THEIR OPPOSITE REGULATION OF PTEN.  
In response to various growth factors and adhesion molecules PI3 kinase is 
activated, which in turn phosphorylates PIP2 to generate PIP3. PIP3 acts as a second 
messenger to recruit PDK-1 kinase to the plasma membrane, and this stimulates PDK-1-
dependent phosphorylation of Akt-1 (reviewed in Cantley, 2002). PIP3 is the major 
substrate of multifunctional phosphatase PTEN; therefore PTEN acts as a major tumor 
suppressor gene by reducing the cellular amounts of a second messenger that induces 
Akt-1 activation, which in turn promotes cell survival and proliferation (Cantley, 2002). 
A recent study showed that loss of PTEN leads to resistance of Notch inhibition in some 
T-ALL cells (Palomero et al., 2007), suggesting, for the first time, a link between Notch-
1 oncogenicity and PTEN activity. We investigated the possibility that activation of 
either Notch-1 or Notch-2 can have opposite effects on Akt -1 phosphorylation due to the 
opposite regulation of the PTEN gene. This was analyzed both at the protein and at the 
mRNA level. We over-expressed Notch-1
IC
 in ME using a doxycycline-inducible 
lentiviral vector. When we induced Notch-1
IC
 we observed a 3.1-fold reduction in PTEN 
protein levels (Fig. 16A, compare lanes b and d).  
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Figure 16. Notch-1 and Notch-2 have opposite effects on PTEN expression both at 
the protein and at the mRNA level. (A) Western blot analysis of the indicated gene 
products of ME14 transduced with either a control lentivirus (pDest) or with a lentiviral 
vector that expressed Notch-1
IC
 upon doxycycline treatment (Notch-1), lanes a-d, or ME 
transfected with either a control siRNA (Control) or a siRNA targeting the Notch-1 
mRNA, lanes e and f. (B) Western blot analysis of the indicated gene products of ME14 
transduced with either a control lentivirus (pDest) or with a lentiviral vector that 
expressed Notch-2
IC
 upon doxycycline treatment (Notch-2). Note clone specific effects of 
doxycycline exposure on PTEN expression (compare A to B). (C) Real time PCR 
analysis of the PTEN mRNA measured in ME14 transfected with a control plasmid 
(black column) or with a plasmid expressing Notch-1
IC
 (gray column). The error bars 
represent standard deviation of 4 independent experiments (ME14, 15, 16 and 17). (D) 
Real time PCR analysis of the PTEN mRNA measured in ME cells transfected with a 
control plasmid (black column) or with a plasmid expressing Notch-2
IC
 (gray column). 
The error bars represent standard deviation of 4 independent experiments (ME14, 15, 16 
and 17). PTEN mRNA levels were normalized for 18S rRNA expression in each 
experiment. P values: * > 0.01; ** > 0.0001. All experiments were performed in hypoxia. 
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Doxycycline appeared to non-specifically up-regulate PTEN in these cells, but this 
effect was mostly suppressed by Notch-1
IC
 over-expression. We measured the PTEN 
mRNA levels in ME transiently transfected with a plasmid expressing Notch-1
IC
 cells and 
we observed a 2.4-fold reduction of the PTEN mRNA (Fig. 16C). When we decreased 
Notch-1 expression using a siRNA targeting Notch-1 in the same cells, we observed a 4.4 
fold increase of PTEN protein expression (Fig. 16A, compare lanes e and f). Opposite 
effects were observed when we expressed Notch-2
IC
 in the same ME cells. Doxycycline-
induced expression of Notch-2
IC
 caused a 4.2-fold increase in PTEN expression (Fig. 
16B), paralleled by a 3.2-fold increase of the PTEN mRNA levels (Fig. 16D).  
Combined, the data suggested that the opposite effects on Akt-1 activation 
mediated by Notch-1 and Notch-2 signaling in ME, and differential effects on ME cell 
survival, could have resulted from an opposite regulation of those two Notch isoforms on 
the PTEN promoter. To ascertain whether such Notch regulation was direct, we assayed 
the PTEN promoter region by ChIP assay. More specifically, we probed the 2646 bp long 
region between positions -3033 and -387 of the PTEN promoter (+1 is the PTEN 
initiation codon) using 11 partially overlapping amplicons derived by the use of 11 oligo 
pairs (Table 6).  
A 215 bp DNA fragment of the PTEN promoter (positions -602 to -387) was co-
immmunoprecipitated alongside Notch-1 in ME14 cultured under hypoxia in three 
independent experiments (Fig. 17). The fragment of the PTEN promoter that Notch-1 was 
found to interact with contains a CBF-1 consensus sequence, suggesting direct regulation 
of the PTEN promoter by Notch-1 in ME cells. 
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Table 6. A list of oligonucleotides used for ChIP experiment on the PTEN 
promoter: 
 
PF1 5’-GTCACTTGGCTGAGTCCACA-3’ 
PF2 5’-TCGGCTGAGAGCTTTCATTT-3’ 
PF3 5’-GTAGTTCTACTTCCTAAGGG-3’ 
PF4 5’-TTCCCCAACTAGGGACACAC-3’ 
PF5 5’-AGGTCGATGTAGAGCAAGGA-3’ 
PF6 5’-TGAGAACCGAGCTTGACTCC-3’ 
PF7 5’-GCAAAAGGAAAGAGCGAATG-3’ 
PF8 5’-ATGTGGCGGGACTCTTTATG-3’ 
PF9 5’-GCCGAGGCTTAGCTCGTTAT-3’ 
PR1 5’-GCAAGCCAAAGGACTGAGAC-3’ 
PR2 5’-CATTCGCTCTTTCCTTTTGC-3’ 
PR3 5’-GTTGCAACAAACGTCCAGTC-3’ 
PR4 5’-GGAGTCAAGCTCGGTTCTCA-3’ 
PR5 5’-GGAACTACTTTCCGAAGGAG-3’ 
PR6 5’-CAGCGTGTATCACCTCATCC-3’ 
PR7 5’-GAGGCGAGGATAACGAGCTA-3’ 
PR8 5’-GAGGCTGCACGGTTAGAAAA-3’ 
PR9 5’-CATAAAGAGTCCCGCCACAT-3’ 
PC1F 5’-TGGGTTTCTGGGCAGAGG-3’ 
PC1R 5’-GGTAGGAGGGGGCAGAGC-3’ 
PC2F 5’-TTCTCCTGAAAGGGAAGGTG-3’ 
PC2R 5’-GGAGGCAGTAGAAGGGGAGAG-3’ 
H1F 5’-AGCGTGGGAAAGGATGGTTG-3’ 
H1R 5’-CTCGCTTCATGCTGGCTCCC-3’ 
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Figure 17. Notch-1 directly interacts with the PTEN promoter within a region 
between position -602 and -387 (+1 is the PTEN start codon). ME14 cells were 
cultured in three 150 mm dishes, incubated in hypoxia for 48 hr, and fixed in 1% 
formaldehyde. Crosslinking was blocked with 250 mM glycine, cells were rinsed with 
PBS and lysed. Cell lysates were combined, DNA was fragmented using a sonicator to 
yield DNA fragments smaller than 600 bp and immunoprecipitated with antibodies and 
controls. After washing Protein A- conjugated sephacryl beads, the DNA-protein 
complexes were eluted from the beads, the crosslinking was reversed overnight at 65° C, 
and DNA was purified using Qiagen columns. Of the 50 µl of the total volume, 2 µl were 
used for PCR reactions (45 cycles). The reactions shown here were obtained using the 
primers PC1F and PC1R (Table 6). No positive amplification was obtained using any 
other couple of primers specified in Table 6, with the exception of the input DNAs in 
three separate experiments. Lanes: M, molecular weight marker; H, H2O as template, 7; 
Rabbit polyclonal antibody anti human IL7 (negative control); G, rabbit pre immune 
serum (negative control); N1, rabbit polyclonal antibody anti human Notch-1 (C20, Santa 
Cruz Biotechnologies); IN, 1/100 of the input DNA. We used as positive control a 167 bp 
amplicon corresponding to bases -157 to +10 of the HEY1 promoter (+1 is the HEY1 
initiation codon) amplified with primers H1F and H1R (Table 6) in each ChIP 
experiment (not shown). 
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DISCUSSION 
In this chapter we show that MM cell survival requires Notch-1 expression and 
signaling. Notch-1 mediates its effects by affecting the Akt-1 signaling pathway through 
regulation of PTEN expression. These results confirm what was observed in T-ALL cells 
(Palomero et al., 2007), and strongly suggest that the crosstalk between Notch-1 and Akt-
1 pathways may be of general validity in cancer and may have far-reaching therapeutic 
implications. 
In contrast to Notch-1, Notch-2 plays a tumor suppressive role in MM, by 
depressing the PIP3/PTEN/Akt-1 axis. Such opposing roles of Notch-1 and Notch-2 in 
cancers are not unprecedented, as it is known that the different Notch receptors display 
diversity in their functions (Shimizu et al., 2002). In breast cancer there is strong 
evidence that Notch-1 and -4 are oncogenic, while Notch-2 may play a tumor suppressive 
role (O’Neil et al., 2007). Biologically, there is evidence that Notch-2 has an opposite 
effect compared to Notch-1 and Notch-4 in breast cancer MDA-MB231 cells (O’Neil et 
al., 2007). Examples of opposite effects of Notch-2 and Notch-1 have been discovered in 
multiple myeloma (Nefedova et al., 2004) and embryonal brain tumors (Fan et al. 2004). 
Biochemically, there is a body of published evidence that the transcriptional activity of 
Notch-2 is dramatically lower than that of Notch-1 or Notch-3 (Shimizu et al., 2002). 
Moreover, expression of Notch-2 together with either Notch-1 or Notch-3 inhibits their 
transcriptional activity (Shimizu et al. 2002). The molecular mechanism(s) for these 
differential effects is not known. It should be pointed out that the postulated trans-
activation domain (TAD) is the least conserved region between Notch paralogs (Kurooka 
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et al., 1998). It has been proposed that all four Notch paralogs bind to CBF-1 (Nam et 
al., 2007). It is possible that either Notch-2 is not as effective as Notch-1 or Notch-3 in 
stabilizing the interaction between MAML1 and CBF-1 or in recruiting coactivators such 
as p300 to the Notch transcriptional complex. Alternatively, it is possible that Notch-2 
does not displace co-repressors such as SMRT from CSL. The molecular composition of 
the Notch transcriptional complex including Notch-1 or Notch-2 at the PTEN promoter 
will have to be determined in future studies. 
It is reasonable to suggest that the cell environment will also contribute to the role 
each Notch receptor plays in any given tumor, and that in certain contexts Notch-1 and 
Notch-2 can have opposite biological effects. The mechanism of these differing effects is 
still unclear. It is not clear whether Notch-2 acts by antagonizing Notch-1 (for example, 
by competing for co-activators and CBF-1) or the two paralogs have independent or 
opposing effects on certain downstream targets.  
Since Notch signaling does not rely on amplification phosphorylation cascades 
(such as the ERK signaling pathway), the strength and duration of Notch stimulation can 
play a critical role. We have shown, as have others, that microenvironmental condition, 
such as hypoxia, can also alter the biological significance of Notch signaling (Gustafsson 
et al., 2005, Chen et al., 2007). For these reasons we have tested our cell systems using 
different levels of expression, different duration of Notch activation and different oxygen 
concentrations. Although quantitatively variable, our results invariably led to the same 
qualitative conclusions (e.g., Notch-1 plays a pro-oncogenic role in MM, while Notch-2 
appears to be oncosuppressive in this malignancy).  
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ChIP assays suggested that Notch-1 could directly regulate PTEN promoter in 
ME. The fragment we co-immunoprecipitated includes the CBF-1 consensus sequence 
(cGtGGGAA), previously shown to be bound by CBF-1 in gel mobility assays in vitro 
(Nam et al., 2007). Using luciferase assays and RT-PCR analysis, Whelan et al. (2007) 
showed Notch-1 direct regulation of the PTEN promoter mediated by CBF-1 binding in 
the same region where we immunoprecipitated Notch-1 in ChIP assays, thus supporting 
our data. On the other hand, in T-ALL cells Notch-1 appears to regulate this promoter 
indirectly through HES-1 (Palomero et al., 2007). It is possible that these apparent 
differences may be tissue-specific. 
Notch-1 inhibition using GSI appeared to induce apoptosis of ME most efficiently 
in hypoxic conditions (Fig. 14B). This may have profound therapeutic implications 
because MM is highly hypoxic (Klabatsa et al., 2006). The availability of a drug that 
specifically targets these malignant cells in hypoxia may prove to be ideal for future 
therapeutic regimens, and may lead to a more rational design of combination therapies. 
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CHAPTER 5 
THE ROLE OF NOTCH SIGNALING IN ADENOCARCINOMA OF THE LUNG 
 
ABSTRACT 
A hypoxic tumor microenvironment supports cancer stem cell survival
 
(Keith and 
Simon, 2007) and causes poor response to standard chemotherapy and tumor recurrence
 
(Milas and Hittelman, 2009). Inhibition of Notch-1 signaling, obtained through genetic 
manipulation or !-secretase inhibitor (GSI) treatment in adenocarcinoma of the lung 
(ACL) cells causes apoptosis specifically under hypoxia. Akt-1 activation is a key 
downstream mediator of Notch-1 pro-survival effects under hypoxic conditions. 
Expression of constitutively active Akt-1 in ACL cells under hypoxia rescued most of the 
toxic effects caused by Notch inhibition. Notch-1 regulates Akt-1 activation through two 
major mechanisms: repression of phosphatase and tensin homolog (PTEN) expression 
and induction of the insulin-like growth factor receptor-1 (IGF-1R). The latter regulation 
seems to be the major determinant of Akt-1 activation in ACL cells, since Notch-1 
signaling deeply affects Akt-1 activation in PTEN
-/-
 ACL cells. Both the downregulation 
of Insulin Receptor Substrate 1 (IRS-1) and dominant-negative IGF-1R sensitized ACL 
cells GSI-induced apoptosis. Conversely, overexpression of IGF-1R under the control of 
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a CMV promoter protected ACL cells from the toxic effects of Notch-1 inhibition. 
Inhibition of Notch-1 (obtained either through genetic manipulation or GSI treatment) 
caused reduced IGF-1R expression, both at the protein and at the mRNA level, while 
forced Notch-1 expression caused opposite effects in a panel of cancer cell lines. ChIP 
experiments suggested Notch-1 direct regulation of the IGF-1R promoter. Experiments in 
which human ACL cells were injected in mice confirmed elevated and specific co-
expression of Notch-1
IC
, IGF-1R and pAkt-1 in hypoxic tumor areas. 
Our data provide a mechanistic explanation for Notch-1 mediated pro-survival 
function in hypoxic ACL tumor microenvironment. The results identify additional 
molecular targets that may synergize with Notch-1 inhibition for ACL treatment. 
 
INTRODUCTION 
Notch signaling is an evolutionarily conserved pathway responsible for critical 
cell fate decisions during development and post-natal life
 
(Artavanis-Tsakonas et al., 
1999). Notch receptors (Notch-1 through -4) and ligands have been linked to cancer, 
although the exact role that each isoform plays seems to be tissue- and context-dependent
 
(Miele et al., 2006). Alteration of expression levels of Notch signaling pathway 
components or their mutations can contribute to tumorigenesis in both positive and 
negative ways. In some organs Notch can serve as  dominant oncogene; in others it can 
act as a tumor suppressor gene, insofar as the outcome of Notch signaling is strictly 
context, time and dosage dependent (Maillard and Pear, 2003). Notch’s role in non-small 
cell lung cancer (NSCLC) still awaits a better understanding. A pro-oncogenic role for 
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Notch-3 has been proposed for a subset of NSCLCs
 
(Dang et al., 2000, Haruki et al., 
2005, Konishi et al., 2007). We showed that targeting Notch-1, either using short hairpin 
RNA (shRNA) or a GSI, caused ACL cells to undergo apoptosis specifically under 
hypoxia
 
(Chen et al., 2007), a condition typical for ACL in vivo
 
(Chen and Dehdashti, 
2005). Re-expression of intracellular (active) Notch-1 (Notch-1
IC
) rescued the pro-
apoptotic effects of GSI
 
(Chen et al., 2007). In this chapter we unveiled the mechanisms 
responsible for Notch-1-dependent pro-survival signals to ACL cells under hypoxia. 
Notch-1 activation in 1% oxygen appears to be hypoxia inducible factor 1& (HIF-1&) 
dependent, because HIF1! siRNA reduced Notch-1IC expression and the Notch 
downstream target Hes-1 (Fig. 18), confirming previous results
 
(Gustafsson et al., 2005).  
 
                         
Figure 18. Notch-1 activation in ACL cells under hypoxia is HIF-1&  dependent. (a) 
Representative Western blot analysis of A549 cells transfected with either a control 
siRNA (cont) or with a siRNA targeting the HIF1! mRNA (siHIF-1&). (b) Quantitative 
RT-PCR of the Hes1 mRNA in A549 transfected with either a control siRNA (cont, black 
column) or with a siRNA targeting the HIF1! mRNA (siHIF-1&, gray column). mRNA 
levels were normalized for 18S rRNA expression levels. Columns represent the average 
of three independent experiments. Error bars represent SD. 
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MATERIALS AND METHODS 
Unless otherwise specified, all experiments were performed in 1% O2, 5% CO2, 
94% N2 (hypoxia). Cells grown in hypoxia were maintained in chambers (Stem Cell 
Technologies) filled with a certified mixture of aforementioned gases (Airgas North 
Central) at 37 °C. MiniOX1 oxygen meters (Mine Safety Appliances Company) were 
used to measure oxygen concentration. The experiments shown here were performed on 
ACL lines A549, H1299 and H1755 (ATCC). Some experiments were performed in ACL 
cell line H1650 (Fig. 24), while other cell lines are specified in Fig. 28. All cell lines 
were fingerprinted using the GenePrint fluorescent STR system (Promega). 
 
OLIGONUCLEOTIDES, ANTIBODIES, PLASMIDS, RETROVIRAL VECTORS AND SIRNAS  
IGF1R-CBF1-Up-F TGTGTGTGTCCTGGATTTGG 
IGF1R-CBF1-Up-R AGAAACGCGGAGTCAAAATG 
IGF1R-CBF1-DWN-F GGTTGCCGAGGGTATGCA 
IGF1R-CBF1-DWN-R GTGAAGGCTCAGTCGTGATTTTT 
IGF1R-CBF1-DWN-probe 6FAM-TGCCGATTAACTTTG-MGBNFQ 
b-globin-F CCAGCCTTATCCCAACCATA 
b-globin-R TATCATGCCTCTTTGCACCA 
 
Table 7. A list of oligonucleotides used for ChIP experiment on the  
IGF-1R promoter 
 
A list of all oligonucleotides used in this chapter is reported in Table 8. A list of 
all antibodies used in this chapter is reported in Table 9.  
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     Table 8. A list of all oligonucleotides used in Chapter 5 
Gene Primer Sequence 
%-globin-F 5’-CCAGCCTTATCCCAACCATA-3’ 
%-globin-R 5’- TATCATGCCTCTTTGCACCA-3’ 
BCL2A1 F 5’-TCTCAGCACATTGCCTCAAC-3’ 
BCL2A1 R 5’-AGTCCTGAGCCAGCCTGTAA-3’ 
Bcl2A1-F-BamH1 5’-GGGGGATCCAATGACAGACTGTGAATTTGG-3’ 
Bcl2A1-R- XhoI 5’-GGGCTCGAGTCAACAGTATTGCTTCAGGAG-3’ 
Casp-1 F 5’-GCTTTCTGCTCTTCCACACC-3’ 
Casp-1 R 5’-CATCTGGCTGCTCAAATGAA-3 
Notch-1 F 5’-TGTTGTGTGTCATGCCAGTG-3’ 
Notch-1 R 5’-AACATCTTGGGACGCATCTG-3’ 
Hes1 F 5’-TCAACACGACACCGGATAAA-3’ 
Hes1 R 5’-CCGCGAGCTATCTTTCTTCA-3’ 
HeyL-F-XhoI 5’-GGGCTCGAGATGAAGCGACCCAAGGAGC-3’ 
HEYL-R-BamHI 5’-GGGGGATCCTCAGAAAGCCCCGATTTCAGTG-3’ 
IGF-1R F 5’-AACCCCAAGACTGAGGTGTG-3’ 
IGF-1R R 5’-TGACATCTCTCCGCTTCCTT-3’ 
IGF1R-CBF1-Up-F 5’-TGTGTGTGTCCTGGATTTGG-3’ 
IGF1R-CBF1-Up-R 5’-AGAAACGCGGAGTCAAAATG-3’ 
IGF1R-CBF1-DWN-F 5’-GGTTGCCGAGGGTATGCA-3’ 
IGF1R-CBF1-DWN-R 5’-GTGAAGGCTCAGTCGTGATTTTT-3’ 
IGF1R-CBF1-DWN-probe 5’-6FAM-TGCCGATTAACTTTG-MGBNFQ-3’ 
PTEN F 5’-ACCAGGACCAGAGGAAACCT-3’ 
PTEN R 5’-GCTAGCCTCTGGATTTGACG-3’ 
18S F 5’-TGATTAAGTCCCTGCCCTTTGT-3’ 
18S R 5’-TCAAGTTCGACCGTCTTCTCAG-3’ 
Human GAPDH F 5’- AGGCCCCGGGATGCTAGTG-3’ 
Human GAPDH R 5’- CACACGCGACTCCACCCATC-3’ 
Mouse GAPDH F 5’-AGCACAACTCAAAACTACCTGCA-3’ 
Mouse GAPDH R 5’- TGAGGTGTTTTGCTCCCAGT-3’ 
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ANTIBODIES 
 
Target Type Company Cat. number 
Notch-1 IC (Val1744) Rabbit polyclonal Cell Signaling 2421 
Acetyl Histone H3 Rabbit polyclonal Millipore 06-599B 
Akt-1 (G-5) Mouse monoclonal Santa Cruz Biotech. 55523 
Bcl2A1 Rabbit polyclonal Abcam 45413 
Bcl-xL (54H6) Rabbit monoclonal Cell Signaling 2764 
Caspase-1 (A-19) Rabbit polyclonal Santa Cruz Biotech. 622 
GAPDH Mouse monoclonal Chemicon MAB374 
GFP Rabbit polyclonal Abcam Ab290 
Glut-1 Rabbit polyclonal Abcam Ab15309 
HIF1& (H-206) Rabbit polyclonal Santa Cruz Biotech. 10790 
HIF1& (H1alpha67) Mouse monoclonal Abcam Ab1 
IGF1R% (C-20) Rabbit polyclonal Santa Cruz Biotech. 713 
IgG Rabbit polyclonal Santa Cruz Biotech. 2027 
IgG Rabbit polyclonal Millipore PP64B 
IgG Mouse polyclonal AbCam 18448 
IRS-1 (H-165) Rabbit polyclonal Santa Cruz Biotech. 7200 
MAML1 Rabbit polyclonal Millipore AB5975 
Mcl-1 (S-19) Rabbit polyclonal Santa Cruz Biotech. 819 
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mTOR (H-226) Rabbit polyclonal Santa Cruz Biotech. 8319 
NF-"B p50 (E-50) Mouse monoclonal Santa Cruz Biotech. 8414 
Notch-1 (C-20) Rabbit polyclonal Santa Cruz Biotech. 6014 
P300 (H-272) Rabbit polyclonal Santa Cruz Biotech. 8981 
PDK-1 Rabbit polyclonal Cell Signaling 3062 
PTEN Rabbit polyclonal Cell Signaling 9552 
PTEN (A2B1) Mouse monoclonal Santa Cruz Biotech. 7974 
p-Akt (Ser473) Rabbit monoclonal Cell Signaling 4058 
p-Akt (Ser473) (D9E) Rabbit monoclonal Cell Signaling 4060 
p-IGF-1R (Tyr980) Rabbit monoclonal Cell Signaling 4568 
p-mTOR (Ser2448) Rabbit polyclonal Cell Signaling 2971 
p-PDK-1 (Ser241) Rabbit polyclonal Cell Signaling 3061 
AlexaFluor 568 Rabbit IgG labeling kit Zenon Z25306 
AlexaFluor 488 Rabbit IgG labeling kit Zenon Z25302 
AlexaFluor 488 mouse IgG labeling kit Zenon Z25002 
 
       Table 9. A list of all antibodies used in Chapter 5 
 
The plasmid encoding constitutively active Akt-1 (myr-Akt1) was from Upstate 
Biotechnology. The plasmid encoding full-length IGF-1R was previously described
 
(Bocchetta et al., 2008), the plasmid encoding dominant-negative IGF-1R was a gift from  
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Dr Hua Zhang (University of Minnesota), the plasmid encoding dominant-negative 
MAML1 was previously described
 
(Weng et al., 2003). The plasmids encoding Hes1 was 
from Invitrogen. The plasmid encoding Hes5 was from OriGene. The plasmid encoding 
c-myc was from AddGene. The plasmid encoding HeyL was obtained by amplifying the 
HeyL cDNA from a liver cDNA library. This cDNA was subsequently cloned in the Xho 
I/Bam HI sites of pcDNA3 (Invitrogen). The Bcl2A1 expressing plasmid was constructed 
following a similar strategy: the complete CDS was PCR amplified from a lung cDNA 
library and cloned into the Bam HI/ Xho I sites of pcDNA4 (Invitrogen). The 
development of stably transduced, tetracycline-inducible ACL cells expressing Notch-1
IC
 
within the pLenti4/TO/V5-DEST (Invitrogen) backbone has been previously described
 
(Chen et al., 2007). siRNA to Notch1 and IRS1 were from Santa Cruz Biotechnology; 
siRNA to HIF1! was from Qiagen, while siRNA negative control was the Allstars 
negative control (Qiagen). Transient transfections were done using an electroporator 
(GenePulserII, Bio-Rad) under the following parameters: 300 kV, 975 µF; 1 µg of 
plasmid DNA/10
6 
cells or 20 pmol siRNA/10
6 
cells. Efficiency of transfection was >95%.  
 
MICE AND MOUSE PROCEDURES  
6 weeks old female NOD.CB17-
Prkdcscid
/J mice (Jackson Laboratories) were 
injected in the tail vein with 5 x 10
6
 cells (A549, H1299, H1755 in separate experiments) 
in 100 µl of sterile saline solution. Mice were housed in a pathogen-free animal facility at 
Loyola University Medical Center. All procedures were done in accordance with the 
Institutional Animal Care and Use Committee of the Loyola University Chicago Medical 
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Center. Animals were monitored until they reached the endpoint (dyspnea). At the time 
of euthanasia, human cells comprised 93±0.8% of the total lungs of mice. Tumor burden 
quantification was performed using quantitative PCR measuring human versus mouse 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. After sequence alignments 
of the human and mouse GAPDH genomic regions (Clustalw software), we designed 
primers discriminating the two genes (Table 8). Primers were carefully validated, and 
calibration curves to match Real Time PCR results to cell number were developed. DNA 
was extracted from the whole left lung, the whole left liver lobe, and the whole left 
cerebral hemisphere of each mouse (Fig. 32 and Table 8). Organs were excised and flash 
frozen. 8µm-thick slides were used for standard immunofluorescence experiments. 
 
CELL VIABILITY STUDIES AND GENE AND PROTEIN EXPRESSION ANALYSIS 
Annexin V/7-aminoactinomycin D (7-AAD) staining (cell viability) assays, 
quantitative RT-PCR (using SYBR green incorporation), Western blot and 
immunohistochemistry assays were performed as described
 
in Chapter 4. Pathway 
specific arrays based on quantitative RT-PCR were from SuperArray. Results were 
confirmed in targeted quantitative-RT-PCR experiments. The GSI MRK-003 was 
dissolved in DMSO to 40 mM final concentration. The working concentrations and the 
duration of exposure used in each experiment are specified in figure legends. 
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CHROMATIN IMMUNOPRECIPITATION (CHIP) EXPERIMENTS 
End-point or Q-PCR based ChIP assays were performed as described
 
in Chapter 4 
with a few modifications. CT values obtained in association with each 
immunoprecipitation reaction were normalized for "globin. The average value of three 
pre-immune IgG was arbitrarily set to 1, and the "globin normalized values of each 
immunoprecipitation reaction were expressed as fold enrichment over the values obtained 
for the pre-immune IgGs. 
 
STATISTICAL ANALYSES. 
Statistical analyses were performed using Student’s t-test. Values were considered 
statistically significant at P < 0.05 in two-tailed tests. 
 
RESULTS 
 
NOTCH NEGATIVELY REGULATES PTEN EXPRESSION IN ACL 
In other systems, including MM, Notch-1 positively regulates Akt-1 activation by 
suppressing PTEN transcription
 
(Chapter 4, Palomero et al., 2007). We asked whether 
Notch-1 influences PTEN expression in ACL cells.  After manipulation of Notch-1 
expression in those cells, both PTEN protein and mRNA expression levels were 
determined (Fig. 19). Artificial downregulation of Notch-1 using specific siRNA caused 
a ~3-fold increase in the PTEN expression, while overexpression of Notch-1
IC
 led to a 
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~5-fold reduction in PTEN expression levels (Fig. 19a). On the contrary, both genetic 
and chemical inhibition of Notch-1 caused an increase in PTEN mRNA expression (Fig. 
19b). 
 
Figure 19. Notch-1 negatively regulates PTEN expression in ACL cells. (a) Western 
blot analysis of the indicated proteins in H1299 cells transfected with a control siRNA 
(cont, left), with a siRNA targeting the Notch1 mRNA (siN1), with a control plasmid 
(cont, right) or with a plasmid expressing Notch-1
IC
 (N1). Bands in Western blot 
experiments were quantitatively evaluated using a FujiFilm LAS-3000 imaging system. 
(b) H1299 cells were transfected with either a control siRNA (cont, left) or with a siRNA 
targeting the Notch1 mRNA (siN1). Alternatively, H1299 cells were treated with either 
DMSO (cont, right) or with 20 µM GSI for 48 hr. The mRNA levels were measured 
using quantitative RT-PCR and normalized for 18S rRNA content. Bars represent 
average of three independent experiments. Error bars represent SD. We obtained similar 
results in A549 and H1755 cells (one experiment for each cell line). 
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NOTCH-1 POSITIVELY REGULATES AKT-1 ACTIVATION IN ACL CELLS 
In parallel, to assess whether Notch-1 can stimulate signaling through Akt-1 
pathway affecting other components, we looked at the upstream activator of Akt-1 
namely phosphoinositide-dependent kinase-1 (PDK-1; Alessi et al. 1997) and 
downstream effector mammalian target of rapamycin
  
(mTOR; Fig. 32a-c; Ruggero and 
Pandolfi, 2003). Forced expression of Notch-1
IC
 using doxycycline inducible system 
caused increased phosphorylation of PDK-1, Akt-1 and mTOR (Fig. 20a, compare lanes 
2 and 4). Notch-1 stimulation of Akt activation is elicited in a dose-dependent fashion 
(Fig. 20b). Inhibition of Notch-1 expression using siRNA resulted in reduced signaling 
through Akt-1 pathway, as judged by a reduced phosporylation of Akt-1, PDK-1 and 
mTOR proteins (Fig. 20c).  
 
 
Figure 20. Notch-1 regulates Akt-1 phosphorylation in ACL cells under hypoxia. (a) 
A549 cells were transduced with an empty lentiviral vector (A549-TR-D) or with a 
lentivirus in which Notch-1
IC
 was under the control of a doxycycline-inducible promoter 
(A549-TR-N1). Upon doxycycline induction of Notch-1
IC
, increased phosphorylation of 
Akt-1, PDK-1 and mTOR was observed (compare lanes 2 and 4). (b) A549-TR-N1 cells 
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were treated with the indicated concentrations of doxycycline. Notch-1 appeared to 
stimulate Akt-1 phosphorylation in a dose-dependent fashion. (c) Notch-1 artificial 
downregulation obtained using a siRNA to Notch-1 caused decreased activation of PDK-
1, Akt-1 and mTOR. A549 cells were transfected with either a commercial control 
siRNA (cont) or a siRNA targeting the Notch-1 mRNA (siN1). Cells were assayed 48 hr 
after transfection using Western blot.  
 
 
Fig. 21. Akt-1 activation protects ACL cells from apoptosis triggered by Notch 
inhibition under hypoxia. Left: Western blot analysis of the indicated proteins in A549 
cells transfected with either a control vector (cont) or with a vector expressing an NH2-
terminal myristoylatable Akt-1 (constitutively active Akt, or aAkt; Chapter 4). Right: 
Annexin V/7-AAD staining of A549 cells transfected with either a control plasmid (cont) 
or with aAkt, and exposed to 20 µM GSI for 48 hr. The histogram represents the average 
of three independent experiments. Error bars represent SD. Black columns: alive cells; 
gray columns: dead cells (annexin V positive).  
 
Activated Akt-1 plays a major role in Notch-mediated protection from apoptosis under 
hypoxia, since transient transfection of ACL cells with an NH2-terminal myristoylable 
Akt-1 (constitutively active Akt-1, or aAkt) rescued 71.59 ± 2.18% cells from GSI-
induced apoptosis (Fig. 21). Importantly hypoxia alone causes more than 6% A549 cell 
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death, suggesting that aAkt can rescue GSI induced cell death almost to the basal level. 
High concentrations of GSI caused nearly complete cell death 48 hr after exposure. Even 
under these conditions, aAkt kept alive about 50% of transfected cells (Fig. 22).  
                        
Figure 22. Constitutively active Akt-1 rescues ACL cells from cell death even at very 
high GSI concentrations (100 µM) under hypoxia. Representative experiment. Top: 
two ACL lines transfected with either a control plasmid (pUSE) or with a plasmid 
expressing constitutively active Akt-1 (aAkt). Western blot analysis of the indicated cell 
lines. Bottom: annexin V/7-AAD staining of A549 cells transfected with the indicated 
plasmids and treated with either vehicle alone (DMSO) or 100 µM GSI. It should be 
noted that the percentage of GSI induced cell death is dependent on GSI concentration 
but also on cell confluency (more confluent cells were more resistant to GSI treatment). 
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In this study we used a GSI concentration of 20 µM and a cell confluency of 70-80% 
in most experiments. Under these conditions hypoxia induces 23±3% cell death in 48 
hours. 
 
 
Percentage of GSI induced cell death depended not only on GSI concentration, but also 
on cell confluency. Taken together, these observations suggest that Akt-1 activation 
could be the major target of Notch-1 induced ACL cells’ resistance to apoptosis under 
hypoxia. 
 
NOTCH-1 REGULATES THE EXPRESSION OF CASPASE-1 AND BCL2-A1 INDIRECTLY 
THROUGH AKT-1 
Through its regulation of Akt-1, Notch-1 indirectly regulated the expression of 
Bcl2-A1 and caspase-1, two proteins that are involved in apoptosis response (Fig. 23). 
Notch-1 inhibition (obtained through shRNA to Notch1 or GSI treatment) resulted in the 
reduced Bcl2-A1 and increased caspase-1 expression. When considered independently, 
those two molecules can rescue only a fraction of GSI-induced ACL cell death under 
hypoxia. Inhibition of caspase-1 (obtained by exposing ACL cells to the caspase-1 
inhibitor Y-VAD) did not significantly rescue GSI induced cell death under hypoxia, 
while transient transfection of A549 cells with a plasmid expressing Bcl2-A1 marginally 
rescued GSI-induced apoptosis under hypoxia (Fig. 23b). Transfection of ACL cells with 
constitutively active Akt-1 produces the opposite effects of Notch-1 inhibition on the 
mRNA expression levels of caspase1 and Bcl2A1 (Fig. 23c). Furthermore, Bcl2-A1 and 
caspase-1 expression appeared to be regulated by Akt-1 activity, a downstream target of 
Notch-1. From these results we concluded that Notch-1 inhibition (GSI- or shRNA-
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mediated) led to increased caspase-1 (a pro-apoptotic protein; Bhanoori et al., 2003) 
and decreased Bcl2-A1 expression (an anti-apoptotic protein
; 
Beverly and Varmus, 2009).   
 
 
Figure 23. Notch-1 inhibition leads to reduced Bcl2-A1 and increased caspase-1 
expression. (a) Left: quantitative RT-PCR performed on A549 cells transduced with a 
control shRNA lentiviral vector (black colums) or with a lentiviral vector expressing an 
shRNA targeting the Notch1 mRNA (gray columns). Results were normalized for 18S 
rRNA content in each sample. Right: Western blot analysis of A549 cells treated either 
vehicle alone (DMSO) or GSI (MRK-003) for 48 hr under hypoxia. Note increased 
expression of caspase-1, while Bcl2-A1 expression levels appear to be undetectable after 
GSI treatment; these results mirror what was observed when targeting Notch1 genetically. 
(b) Annexin V/7-AAD staining of A549 cells exposed to 20 µM GSI for 48 hr in hypoxia 
and: vehicle alone (DMSO); 92 µM Ac-YVAD-CMK (Alexis Biochemicals; Y-VAD); 
transfected with pcDNA3 (cont) or with a plasmid overexpressing Bcl2A1. Black colums, 
alive cells; gray columns, Annexin V positive cells. (c) Quantitative RT-PCR of the 
indicated mRNAs in A549 cells transfected with either a control vector (pUSE) or with a 
vector expressing aAkt. All histogram columns in this figure represent averages of 3 
independent experiments. Error bars represent standard deviation. *: P<0.01; **: P<0.05. 
 
 
None of these two proteins (taken individually) appeared to play a major role in the pro-
apoptotic effects of Notch-1 inhibition in ACL cells under hypoxia. Bcl2-A1 and 
caspase-1 appeared rather to be downstream effectors of Akt-1. Since we determined that 
Akt-1 is a major target of Notch-1 signaling in ACL cells under hypoxia, we inferred that 
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both caspase-1 and Bcl2-A1 are indirectly regulated by Notch-1 through Akt-1. It is 
likely that those two proteins participate in the anti-apoptotic effects of Notch-1 signaling 
in ACL cells under hypoxia, although none of them seemed to have a predominant effect 
in this phenomenon when studied individually. 
 
HYPOXIA/NOTCH-1 REGULATES IGF-1R EXPRESSION 
To test whether Notch-1 regulation of Akt-1 activation was mainly a result of 
Notch-1 control of PTEN expression, we modulated the expression of Notch-1 in PTEN
-/-
 
ACL cell line H1650
 
(Guo et al., 2008). Even in cells lacking the expression of PTEN, 
manipulation of Notch-1 expression levels still resulted in altered expression levels of the 
Akt-1 pathway components. Downregulation of endogenous Notch-1 using siRNA led to 
decreased phosphorylation of PDK-1, Akt-1 and mTOR, while forced expression of 
Notch-1
IC
 led to the opposite effects (Fig. 24). These results suggest that factors other 
than PTEN were responsible for Notch-1-mediated Akt-1 activation in ACL cells under 
hypoxia.  
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Figure 24. Notch-1 modulates the activation levels of PDK-1, Akt-1 and mTOR in 
PTEN null ACL cells. Western blot analysis of the indicated proteins. Antibodies 
against phosphorylated forms of the indicated proteins are labeled p. H1650 cells were 
transfected with either a control siRNA (cont), with a siRNA targeting the Notch1 mRNA 
(siN1), with a control plasmid (pcDNA) or with a plasmid expressing Notch1
IC
 (N1IC). 
Cells were analyzed 48 hr after transfection.  
 
In several models activation of the IGF-1R and its adaptor protein IRS-1 induce 
the majority of Akt-1 signaling
 
(Adams et al., 2000). We hypothesized a possible 
crosstalk between Notch-1 and IGF-1 signaling because IGF-1 autocrine signaling can 
regulate HIF-1& expression (Treins et al., 2005). Furthermore, hypoxia increases the 
expression of an IGF-1 and IGF-1R
 
(Moromisato et al., 1996; Fig. 25a). Culturing cells 
under low oxygen condition causes increase in IGF-1R protein expression (Fig. 25a, top), 
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as well as 3.5 fold in the expression of IGF1R mRNA (Fig. 25a, bottom). Both 
transient siRNA to IRS1 and dominant-negative IGF-1R sensitized ACL cells to GSI 
treatment (Fig. 25b-c), reinforcing the possible link between IGF-1R and Notch-1 
signaling. On the other hand, expression of IGF-1R under the regulation of a CMV 
promoter protected ACL cells from GSI-induced apoptosis (not shown). 
 
 
Figure 25. Hypoxia/Notch-1 regulates IGF-1R expression; manipulation of IGF-1R 
signaling modulates the rate of GSI induced cell death under hypoxia. (a) A549 cells 
cultured in a standard incubator or under hypoxia. Top:  representative Western blot 
analysis of the indicated proteins; bottom, quantitative RT-PCR of the IGF-1R mRNA in 
A549 grown either in normoxia (21% O2, black column) or under hypoxia (1% O2, gray 
columns). Messenger RNA levels were normalized for 18S rRNA content. Columns 
represent the average of three independent experiments. Error bars represent SD. (b) 
siRNA to IRS1 sensitizes ACL cells to GSI induced cell death under hypoxia. A549 cells 
were transfected with either a control siRNA (cont) or with a siRNA targeting the IRS1 
mRNA. Top: representative Western blot analysis of the indicated proteins; bottom: 
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Annexin V/7AAD staining of cells transfected with siRNA and exposed to 20 µM GSI 
under hypoxia for 48 hr. Black column, alive cells; gray column, Annexin V positive 
cells. Columns represent the average of three independent experiments. Error bars 
representing SD. P value is indicated. (c) Dominant negative IGF-1R sensitizes ACL 
cells to GSI induced cell death under hypoxia. A549 cells were transfected with either a 
control plasmid (cont) or with a plasmid expressing a dominant-negative IGF-1R. Top, 
representative Western blot analysis of the indicated proteins; bottom, Annexin V/7AAD 
staining of cells transfected with plasmids and exposed to 20 µM GSI under hypoxia for 
48 hr. Black column, alive cells; gray column, Annexin V positive cells. Columns 
represent the average of three independent experiments. Error bars represent SD. P value 
is indicated. (d) Notch-1 regulates the expression of the IGF-1R both at the protein and at 
the mRNA levels. Top: representative Western blot of the indicated proteins in A549 
cells trasfected with a control plasmid (cont, left) or with a plasmid expressing Notch-1
IC
 
(N1IC), or transfected with a control siRNA (cont, right) or with a siRNA targeting the 
Notch1 mRNA (siN1). Bottom: quantitative RT-PCR of the IGF1R mRNA in A549 
transfected with the nucleic acids described above. Additionally, A549 were exposed to 
DMSO (c) or with 20 µM GSI (GSI) for 48 hr under hypoxia. mRNA values were 
normalized for 18S rRNA expression levels. *: P< 0.001; **: P< 0.001; ***: P< 0.01. 
Columns represent the average of three independent experiments. Error bars represent 
SD. All experiments shown in Figure 25 were confirmed in H1299 and H1755 cells (one 
experiment for each cell line). 
 
We then asked if Notch-1 could regulate the expression of IGF-1R. We 
determined that siRNA to Notch1 reduced the expression of IGF-1R protein and mRNA 
(Fig. 25d). Similar effect on IGF-1R expression was observed when cells were treated 
with GSI (Fig. 26a). Those results were reproduced in two other cell lines (Fig. 26a), 
suggesting a more general role of this phenomenon. In other ACL cell lines tested, 
expression of IGF-1R increased when Notch-1
IC
 was overexpressed, while the IGF-1R 
expression level was reduced by GSI treatment. To determine whether the effects on IGF-
1R expression are mediated specifically by Notch-1 isoform, we forced the expression of 
Notch-1
IC
, and found increased IGF-1R protein and mRNA levels (Fig. 25d, Fig. 26a). 
Furthermore, the GSI-induced repression of IGF-1R expression was reversed after 
induction of Notch-1
IC
 (Fig. 26b). Doxycycline treatment alone reduced the IGF-1R 
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expression levels in control cells, suggesting that it can nonspecifically affect IGF-1R 
expression. However, induction of Notch-1
IC
 (obtained through doxycycline treatment) 
led to a ~5-fold increase in the IGF-1R expression levels (Fig. 26 b, compare lanes 3 and 
4). Notch-1
IC
 failed to restore the IGF-1R expression levels completely, possibly because 
of the compounding doxycycline effects (compare lanes 1 and 2). 
 
 
 
 
                               
Figure 26. Notch-1 regulates IGF-1R expression. (a) Western blot analysis of the 
indicated proteins. H1755 and H1299 cells were either transfected with a control plasmid 
(N1IC -) or with a plasmid expressing Notch-1
IC
 (N1IC +). Additionally, A549 cells were 
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treated with either DMSO (GSI -) or 20 µM GSI for 48hr (GSI +). All experiments 
were performed in hypoxia. The two panels for IGF-1R represent two different exposure 
times of the same gel. (b) A549-TR-DEST (lanes 1 and 2) and A549-TR-N1 (lanes 3 and 
4) were exposed to either 1 µg/ml doxycycline (DOX), 20 µM GSI or both for 48 hr. All 
experiments were performed under hypoxia. 
 
Collectively, this data suggest Notch-1 regulation of IGF-1R expression under 
hypoxia. To explain the contribution of HIF-1& to this observation we down-regulated 
HIF1! using siRNA. ACL cells with downregulated HIF-1& showed reduced IGF-1R 
expression (Fig. 27), further confirming the cooperation between HIF-1& and Notch-1 
signaling under hypoxia
 
(Chen et al., 2007; Gustafsson et al., 2005).  
 
                                              
Fig. 27. Artificial down-regulation of HIF-1&  causes reduced expression of the IGF-
1R in ACL cells under hypoxia. A549 cells were transfected with either a control 
siRNA or with a siRNA targeting the HIF1! mRNA. 48 hr after transfection cells were 
assayed by Western blot analysis for the indicated proteins. 
 
Notch-1 regulation of IGF-1R expression was not restricted to ACL cells, since 
siRNA to Notch-1 depressed the IGF-1R expression in cell lines of different tissue 
derivation (Fig. 28). Down-regulation of Notch-1 caused (to different extents in different 
cell lines) reduction of the IGF-1R expression levels. Notably, in 293FT cells (human 
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embryonic kidney cell line stably expressing SV40), we observed the opposite effect 
(down-regulation of Notch-1 caused increased expression of the IGF-1R). This result 
(which still suggests Notch-1 regulation of the IGF-1R promoter) is not surprising, 
because Notch-1 has been described to occasionally cause opposite effects in different 
tissues due to context-dependent reasons. 
 
 
Figure 28. Notch-1 regulates IGF-1R expression in cell lines obtained from different 
tissues. HeLa (cervical cancer), MCF7 (breast cancer), ME16 (malignant mesothelioma) 
CaSki (cervical cancer) cells were transfected with either a control siRNA or with a 
siRNA targeting the Notch1 mRNA. 48 hr after transfection cells were assayed by 
Western blot analysis for the specified proteins. Experiments were performed under 
hypoxia.  
 
NOTCH-1 DIRECTLY REGULATES IGF1R TRANSCRIPTION  
To investigate the mechanisms through which Notch-1 regulates IGF-1R 
expression we transfected ACL cells with known Notch downstream targets (namely, 
Hes-1, Hes-5, Hey-1, Hey-L and c-Myc
 
(Klinakis et al., 2006; Palomero et al., 2006)). 
None of these proteins significantly affected IGF-1R expression levels, neither at the 
protein nor at the mRNA level (not shown). We then hypothesized a Notch-1 direct 
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regulation of the IGF1R promoter. There are two canonical CBF-1 consensus 
sequences in the DNA region surrounding the IGF1R initiation codon (position +1): one 
at position -612 and a second at position +1478 (Fig. 29). 
 
Figure 29. Region of the IGF1R that we analyzed by ChIP for the indicated proteins. 
We focused our attention on two DNA fragments containing canonical CBF-1 binding 
sites. Gray: region upstream of the initiation of transcription; darker pink: 5’ UTR; lighter 
pink: first fragment of the CDS (+1, initiation of translation); green: 5’ region of the first 
intron. (a) At the +1478 region we detected association of Notch-1, MAML-1 and p300. 
Upon transfection with dominant negative MAML-1 (DN-MAML-GFP) (b) these 
proteins are no longer associated with this DNA region, and the amount of acetylated 
histone H3 is significantly reduced (see Fig. 30).  
Notably, we failed to detect association of HIF-1& to the +1478 site in two independent 
ChIP experiments. This suggests that HIF-1& is not directly a part of the protein complex 
present in this DNA region. Courtesy of Shuang Liang. 
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 We analyzed the association of Notch-1
IC
 with these DNA regions using ChIP. We 
found no association of Notch-1
IC
 with the -612 site in 7 independent experiments. 
Instead, Notch-1
IC
 reproducibly associated with the +1478 site (Fig. 30, and Fig. 31a).  
                                        
                                          
 
Figure 30. Notch-1 associates with the +1478 region of the IGF1R gene. End point 
PCR-based ChIP experiment performed on A549 cells. We used two pre-immune IgG; 
one from Millipore (IgG M) and one from Santa Cruz Biotechnology (IgG SC). Notch-1 
was immunoprecipitated using the antibody C-20 (Santa Cruz Biotechnology). In this 
experiment the +1478 region was amplified using primers different to those used in Fig. 
31 (Table 7). 1/20 of input DNA was amplified using end point PCR. Experiment 
performed by Sandra Eliasz and Shuang Liang. 
 
We sought additional evidence that Notch-1
IC
 stimulates transcription of the 
IGF1R gene when associated with the +1478 region. To this end, we immunoprecipitated 
Notch transcriptional coactivators including MAML-1
 
(Nam et al., 2006) and p300
 
(Fryer 
et al., 2002); the +1478 DNA region coimmunoprecipitated with both proteins (Fig. 31a).  
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Figure 31.  Notch-1 associates with the +1478 region of the IGF1R gene alongside 
MAML-1 and p300; transfection of ACL cells with dominant negative MAML-1 
disrupts such assiociation. (a) Quantitative ChIP of the +1478 region (62 bp-long 
TaqMan fragment) after immunoprecipitation of the indicated proteins in A549 cells 
transfected with a control plasmid (black columns) or with a plasmid coding for dominant 
negative MAML-1 (gray columns). The IgG column represents the average of three 
different pre-immune IgG. Each column represents the average of four (black columns) 
or five (gray columns) independent experiments (IgG bar represents 8 independent 
immunoprecipitations). Error bars represent SD. (b) Representative Western blot analysis 
of A549 cells transfected with either control plasmid or the plasmid expressing dominant 
negative (dn) MAML-1 (visualized with an antibody against GFP). Note that upon 
dnMAML-1 expression (24 hr after transfection), the expression levels of IGF-1R are 
substantially decreased. All the experiments shown in this figure were conducted 24 hr 
after transfection. This was because dnMAML-1 appeared to be toxic to ACL cells for 
longer timepoints after transfection. Courtesy of Shuang Liang 
.  
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Transfection of ACL cells with a dominant-negative MAML-1 (dnMAML-1) 
prevented the immunoprecipitation of the +1478 region with Notch-1
IC
, dnMAML-1 and 
p300, and significantly decreased the amount of acetylated histone H3 at this site (Fig. 
31a). This result can be explained by the requirement of a complete protein complex for 
stable Notch-1 association with the +1478 region. Dominant negative MAML-1 lacks its 
central domain responsible for p300 recruitment, which is replaced by green fluorescence 
protein (GFP; Weng et al., 2003). Alternatively, the absence of p300 activity at this site 
may decrease the overall acetylation of histone H3 (Fig. 31a) leading to a local 
rearrangement of the chromatin structure that could render this region less accessible to 
transcription factors/coactivators. Furthermore, transfection of ACL cells with dnMAML-
1 reduced the IGF-1R expression (Fig. 31b). Collectively, the above data suggest that 
Notch-1 directly regulates IGF1R transcription through its association with the +1478 
DNA region. 
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IN VIVO MOLDEL OF ACL 
We then asked if the HIF-1&/Notch-1/IGF-1R/Akt-1 circuitry would be active in 
vivo in experimentally induced, human metastatic ACL in mice (Fig. 32).  
                     
 LUNG LIVER BRAIN 
Human/mouse cells 93 ± 0.8% 1.32 ± 0.082% 0.37 ± 0.22% 
 
Figure 32. Metastatic ACL model in immunocompromized mice. Top: frontal and 
side view of non-inflated lungs obtained from a mouse after euthanasia 18 weeks after 
tail injection of 2.5x10
6
 A549 cells. At this stage mice (which were previously monitored 
daily and did not show signs of pain or distress) displayed mild dyspnea and irritability. 
Since the whole lung appears to be mostly embodied in tumor masses, we decided to 
include dyspnea associated to irritability (rapid movements, unwillingness of the mice to 
be taken by the tail) as an additional endpoint for humanitarian reasons. However, the 
size of the tumor was such that areas of hypoxia within the tumor masses were likely 
present. The overall size of the tumors was the equivalent of a T1 (no larger than 3 cm) 
stage according to the WHO/International Association for the Study of Lung Cancer 
(http://my.iaslc.org/nav/index.pyt). Bottom: tumor burden quantification was performed 
using quantitative PCR measuring human versus mouse glyceraldehyde-3-phosphate 
dehydrogenase  (GAPDH) gene.  After sequence alignments of the human and mouse 
GAPDH genomic regions (Clustalw software), we designed primers discriminating the 
two genes (Table 8).  Primers were carefully validated, and calibration curves to match 
Real Time PCR results to cell number were developed. The template total genomic DNA 
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was represented by three independent aliquots of DNA extracted from the whole left 
lung lobe, the whole left liver lobe, and the whole left cerebral hemisphere of each 
mouse. 
 
 
To this end, we performed a number of immunofluorescence experiments on snap 
frozen, 8 µm thick tissue slides obtained from total of 6 mice. We used GLUT-1 as a 
marker of hypoxia
 
(Ebert et al., 1995; Behrooz and Ismail-Beigi, 1999) because it reliably 
evidenced hypoxia in ACL cells, and because it was co-expressed with HIF-1& in tumor 
samples (Fig. 33).  
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Figure 33. GLUT-1 is an effective marker of hypoxia in ACL cells. (a-d) 
immunofluorescence performed using an anti-GLUT-1 antibody on A549 cells cultured 
in 21% oxygen (a and c) and in 1% oxygen (b and d). (a and b) pre-immune IgG 
(negative control). Original magnification: 100X. (e) Western blot analysis of the 
indicated proteins performed on H1299 cells cultured at the specified oxygen 
concentrations. Courtesy of Shuang Liang. 
 
 
GLUT-1 was co-expressed with HIF-1a in tumor samples (Fig. 34a). Strikingly, 
only hypoxic tumor areas expressed Notch-1
IC
, maximally expressed IGF-1R, and 
appeared to be the only tumor areas where Akt-1 phosphorylation was detectable (Fig. 
34b-e). On the contrary, PTEN was never expressed in tumor areas that were 
characterized by expression of hypoxic by marker GLUT-1 (Fig. 34f). IGF-1R appears to 
be expressed also in non-hypoxic tumor areas. This suggests that Notch-1 is not the sole 
regulator of IGF-1R expression. Upon stimulation, IGF-1R undergoes internalization, 
degradation and recycling (Carelli et al., 1999; Romanelli et al., 2007). These phenomena 
may artificially reduce the level of co-expression that we detected in our 
immunofluorescence experiments. Furthermore, Akt-1 activation appears to be 
maximally sustained in cells actively recycling IGF-1R
 
(Romanelli et al., 2007). 
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Figure 34. Notch-1
IC 
is coexpressed in hypoxic tumor cells together with IGF-1R and 
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phosphorylated Akt-1. Coimmunofluorescence stainings of the indicated proteins on 
8 mm-thick slides obtained from tumor-bearing lungs of SCID mice injected with A549 
cells through the tail vein. (a) coexpression of GLUT-1 and HIF-1a. (b) Co-expression of 
GLUT-1 and Notch-1
IC
. (c) Expression of IGF-1R is maximal in GLUT-1 expressing 
tumor cells. (d) Phosphorylated (S473) Akt-1 is detected in GLUT-1 expressing 
(hypoxic) tumor cell only. (e) PTEN is expressed in GLUT-1 negative tumor cell only. 
Note that GLUT-1 and PTEN positive cells appear to be contiguous. This is likely an 
event due to the lateral, asymmetric nature of Notch signaling. In these experiments we 
detected co-expression rather than co-localization because the different proteins assayed 
here have different cellular localization (e.g., cell surface receptors, cytoplasmic proteins, 
nuclear transcription factors). Bar, 20 mm. Courtesy of Shuang Liang. 
 
 
 
DISCUSSION 
In summary, results presented in Chapter 5 indicate that hypoxia (through HIF-1&) is 
a major determinant of Notch-1 activation in vivo. This leads to strong Akt-1 activation 
in part through PTEN repression but prevalently because Notch-1 regulates IGF-1R 
expression (Fig. 35).  
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Fig. 35. Schematic of Notch-1 regulation of Akt-1 activation under hypoxia in ACL  
 
Our data suggest that in hypoxic tumor microenvironment HIF-1& potentiates the 
transcriptional activities of Notch-1
IC
. This leads to two major events: suppression of 
PTEN expression and, more importantly, upregulation of IGF-1R. Both events lead to 
hyper-activation of Akt-1 in hypoxic tumor environment (Fig. 34). Our data have 
potentially far-reaching implications for understanding the pathogenicity of ACL, and 
can help to develop novel therapeutic strategies. Hypoxic tumor areas are likely to be 
most resistant to apoptosis because of exacerbated Akt-1 activation, as a result of the 
HIF-1&/Notch-1/IGF-1R circuitry. Our data suggest that chemotherapeutic intervention 
that ultimately reduces the oxygen concentration within the tumor might s   c x=v activate 
Notch in hypoxic tumor tissue and promote the survival of tumor cells. This would 
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explain recent data indicating that angiogenesis inhibitors, although reducing the size 
of the primary tumors, appear to promote tumor invasiveness and metastasis
 
(Paez-Ribes 
et al., 2009; Ebos et al., 2009). This effect could be mediated by Notch-1 promotion of 
metastases observed under hypoxia
 
(Sahlgren et al., 2008). Markedly, hypoxia also 
promotes the “stem-like” phenotype of putative tumor-initiating cells
 
(Keith and Simon, 
2007). In other models, such as breast, these cells are highly Notch signaling dependent
 
(Korkaya and Wicha, 2009). While such cells in NSCLC haven’t been definitively 
identified, it stands to reason that if a slowly proliferating, highly drug-resistant cell 
population exists within hypoxic tumor areas, the HIF-1&-Notch-IGF-1R-Akt-1 pathway 
may be involved in their maintenance. Inhibiting Notch-1 through a GSI or other 
pharmacological interventions in ACL may preferentially target hypoxic areas and the 
tumor-initiating cells within them. For this reason, the use of Notch inhibitors in 
combinations with inhibitors of the IGF-1/Akt-1 pathway and/or cytotoxic chemotherapy 
may result in synergistic anti-tumor effects in ACL. 
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CHAPTER 6 
GENERAL CONCLUSIONS 
 
 In my experiments throughout my PhD studies I have established that 
there is a molecular circuitry that intimately involves insulin-like growth factor-1 (IGF-1) 
and Notch-1 signaling interplay in two thoracic malignancies of different histological 
derivation, namely malignant mesothelioma (MM) and non-small cell lung cancer 
(NSCLC). In MM activation of the IGF-1/IGF-1R/Notch-1 axis seems to be required for 
the maintenance of the malignant phenotype, irrespective of whether malignant 
transformation is virally driven or caused by sporadic mutations. I have established that 
in MM Notch-1 is an oncogene, while Notch-2 is a tumor suppressor. Accordingly, 
Notch-1 expression and activation is always present in mesothelial malignant settings, 
while Notch-2 expression is lost. Notch-1 activation appears to have effects on cell 
proliferation and survival (the latter phenomenon in hypoxic conditions) mainly affecting 
the PI3K/PDK-1/Akt-1 signaling axis. A similar situation takes place in NSCLC, where 
Notch-1 provides critical pro-survival signals through the Akt-1 activation. In both 
malignancies Notch-1 affects Akt-1 activation by depressing phosphatase and tensin 
homolog (PTEN) transcription and by positively regulating insulin-like growth factor 
receptor-1 (IGF-1R) expression (Fig. 34). To the best of my knowledge, this is the first 
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time that Notch-1 has been implicated in the regulation of the IGF-1R. The PTEN 
data confirm what was observed in T cell acute lymphoblastic leukemia (T-ALL; 
Palomero et al., 2007). Since these mechanisms have been found in three different 
malignancies (T-ALL, MM, and NSCLC), and they likely represent a universal way 
through which Notch-1 promotes tumorigenicity. In some tissues, such as skin (Nickoloff 
et al., 2002; Rangarajan et al., 2001), pulmonary neoroendocrine cells (Kunnimalaiyaan 
and Chen, 2007), possibly medullary thyroid cells (Kunnimalaiyaan et al., 2007) Notch-1 
acts as a tumor suppressor gene. It is possible that in these tissues Notch-1 regulates 
PTEN and IGF-1R in opposite ways that those that I described. A hint that this could be 
the case is provided by the results we obtained in 293 kidney cells: downregulation of 
Notch-1 caused increased expression of the IGF-1R (e.g., the opposite of what is shown 
in Fig. 25, 26, 28). The reason of these apparently contrasting regulations may be the 
results of interactions with tissue specific transcription factors at the IGF-1R or PTEN 
promoter. A good example in support of this interpretation is provided in breast cancer. 
Estrogen depresses Notch-1 activity (Rizzo et al., 2008). However, in the absence of 
estrogen, Notch-1
IC
 interacts with estrogen receptors ER& alongside I"B kinase & 
(IKK&) to promote estrogen receptor & (ER&)-specific transcription (Hao et al., 2009). 
 Finally, my data provide further explanations on why primary human mesothelial 
cells are uniquely susceptible to SV40-mediated transformation (Bocchetta et al., 2000). 
SV40 upregulates Notch-1 (Bocchetta et al., 2003) and IGF-1R (Porcu et al., 1992). My 
data show that the SV40 Tag (together with cellular p53), also upregulates IGF-1, thus 
exacerbating the IGF-1/IGF-1R autocrine loop. 
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 Altogether, my data and those provided by my colleagues in Dr Bocchetta’s 
laboratory have provided a mechanistic explanation of Notch-1 mediated pro-oncogenic 
activities and have identified novel targets for therapy of such deadly diseases such as 
MM and NSCLC. In this process, I uncovered a novel viral mechanism to support 
cellular transformation. 
 Future directions include: testing in the animal model whether GSI treatment can 
actually specifically target hypoxic tumor tissue. Additionally, it would be important to 
study whether Notch-1 is a master regulator of tumor cell metabolism. IGF-1 and insulin 
signaling pathways are very ancient in the evolution of Metazoa (Pollak, 2008). During 
evolution, insulin receptor (IR) and IGF-1R have diverged to regulate mainly 
carbohydrate metabolism or cellular survival and proliferation, respectively. However, 
these two receptors share very similar downstream signaling components. More 
importantly, hybrid receptors comprised of IR and IGF-1R heterodimers are common in 
cells expressing both receptors, including cancer cells (Adams et al., 2000). It will be 
important to explore whether Notch-1 participates in the regulation of IR as well.
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